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ABSTRACT 
Particle-based delivery systems have been investigated for their potential to 
increase the efficacy of patient diagnoses and treatments. In many cases, these systems 
increase the bioavailability and/or decrease the toxicity of clinically relevant drugs. 
These developments have led to improvements in patient compliance, morbidity, 
mortality, and quality of life. To date, particle-based delivery systems have been 
evaluated in hundreds of clinical trials around the world. Unlike conventional delivery 
systems, particle-based delivery systems offer increased surface area, colloidal 
stability, and system tunability, all of which can be tailored to target the disease state 
of interest and specific patient population.  
Although there are examples of successful particle-based drug products, there are 
numerous obstacles that consistently shunt the ability for these systems to be 
translated from benchside to bedside. Two consistent obstacles are drug toxicity and 
scale-up manufacturing. Drug toxicity is largely caused by inefficient targeting, 
inopportune routes of administration (i.e. oral delivery for a pulmonary disease), and 
unfavorable release mechanisms. Scale-up manufacturing is a continual industrial 
interest, given that particle-based drug products are increasing in popularity, however 
scale-up procedures are still in development and face their own challenges. A potential 
method to overcome the obstacles faced in drug delivery is the development of new 
polymers, either by synthesis of novel entities or derivatization of current ones. To 
ensure biocompatibility, the latter is a common practice. Biopolymers such as 
chitosan, hyaluronic acid, poly(lactic-co-glycolic acid) (PLGA), and naturally 
occurring polysaccharides undergo modifications to achieve desirable characteristics 
  
 
for drug delivery. Acetalated dextran (Ac-Dex) is a synthetic biopolymer derived from 
dextran, a naturally produced hydrophilic polysaccharide. Following a one-step 
reaction, the hydroxyl moieties of dextran are converted to acetal groups, transitioning 
the biopolymer from hydrophilic to lipophilic solubility. Hydroxyl moieties still 
present on the backbone can provide a handle for ligand attachment to actively target 
specific sites of the body. Additionally, controlling the reaction time and altering the 
molecular weight of the dextran backbone can alter the degradation kinetics, providing 
flexibility to achieve desirable release kinetics for a therapeutic of interest. Overall, 
Ac-Dex demonstrates cost-effective and efficient synthesis, easy tunability for 
targeting, and flexibility in controlling release kinetics, all of which propitiate its 
promise as a drug carrier.  
The purpose of this dissertation was to utilize the advantages of Ac-Dex to 
investigate its potential as a drug carrier to overcome challenges that exist in the field 
of drug delivery. Manuscript 1 focuses on decreasing drug toxicity using active 
targeting. Here, Ac-Dex nanoparticles (NP) were synthesized and coated with 
phosphatidylserine to instigate macrophage uptake for the potential to treat diseases 
that use these cells as reservoirs, such as tuberculosis and HIV. Manuscript 2 focuses 
on the synthesis of Ac-Dex microparticles (MP), followed by an exploration of their 
ability to modulate the release of water-soluble cargo. Ac-Dex MP were synthesized 
via spray drying and were loaded with a water-soluble dye. Following the synthesis, 
MP were evaluated for their characteristics and drug release behaviors in multiple pH 
environments. Manuscript 3 uses Ac-Dex as an economical model drug carrier and 
focused on studying the effects of tangential flow filtration (TFF) parameters (factors) 
  
 
on the characteristics of NP (responses) to explore its promise as a scale-up 
purification technique. The final manuscript focuses on the physical characterization 
and development of nanocomposite microparticle system for localized delivery of the 
small molecule Eact, a potential therapeutic for pulmonary arterial hypertension.  
 Previously published reports show that Ac-Dex demonstrates significant promise 
as a versatile, cost-and time-effective, and promising drug carrier for a range of 
applications and disease states. The manuscripts in this dissertation all explore 
uncharted territories of Ac-Dex’s potential, further demonstrating its versatility and 
promise to overcome current drug delivery obstacles.  
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PREFACE 
This dissertation has been written in manuscript style format. Chapter 1 is an 
introduction to the dissertation. Chapter 2 entitled “Particle technology and routes of 
administration: parenteral and pulmonary delivery” is an in-depth introduction to both 
parenteral and pulmonary administration routes for particle technology, both of which 
are partially adopted from Chapter 6 of the book “Nanoparticles for Biomedical 
Applications.” Chapter 3 entitled “Enhancement of Macrophage Uptake via 
Phosphatidylserine-Coated Acetalated Dextran Nanoparticles” was accepted to Journal 
of Drug Delivery Science and Technology in January 2019. Chapter 4, entitled 
“Sustained Release of Water-Soluble Therapeutics via Dry Powder Aerosol Acetalated 
Dextran Microparticles” was submitted to Drug Development and Industrial Pharmacy 
in April 2019. Chapter 5, entitled “Comparison of Nanoparticle Purification Process 
via Centrifugation and Tangential Flow Filtration: A Case Study of Acetalated 
Dextran Nanoparticles” was submitted to Particuology in April 2019. Chapter 6 
entitled “Physical Characterization and Formulation Development of Eact for the 
Treatment of Pulmonary Arterial Hypertension” shows preliminary data pertaining to 
the project. Chapter 7 includes conclusions and future work related to this dissertation. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Motivation 
Following the introduction of particle-based delivery systems, the field of drug 
delivery has significantly improved the pharmacological and pharmacokinetic 
outcomes of therapeutics by decreasing drug toxicity and increasing bioavailability (1, 
2). Drug formulations that involve particle-based technology provide multiple 
advantages over conventional dosage forms (2, 3). By using particle-based delivery 
systems, drug formulations experience a decrease in overall size (several to 100’s of 
microns to single microns or nanometer diameters), allowing for an increase in 
surface-area-to-volume ratio, providing an increase in dispersion, absorption, and 
overall bioavailability (4, 5). Utilizing particle size and composition, particle-based 
delivery systems can passively target tissues using endogenous uptake phenomena (6). 
For example, passive targeting has been shown to decrease drug toxicity, particularly 
for cancer, through the use of enhanced permeability and retention (EPR) effect (7–
11). An example of this occurrence is the mechanistic enhanced uptake of Doxil®, 
liposomal doxorubicin, into cancerous tissue (12, 13).  
Although drug toxicity and bioavailability are major obstacles that need to be 
overcome using particle-based delivery systems, the former is still a concern. Major 
causes of drug toxicity relate to unwanted drug deposition, unfavorable release 
kinetics/mechanisms, and less ideal routes of administration (i.e. oral delivery for 
pulmonary disease states) (2, 14, 15). As a result, there has been a rise in the 
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development of novel strategies to increase the quality of drug delivery systems to 
enhance the effectiveness of disease treatment while decreasing the likelihood of drug 
toxicity (2). Strategies to improve particle-based technologies in this regard include i) 
surface targeting mechanisms (peptides, small molecules, antibodies, etc.) (16–18) 
(drug targeting); ii) external stimulation (radio frequency, ultrasound, ultraviolet light, 
etc.), environmental stimulation (oxidation, pH, enzymatic processes, etc.) and the 
development and utilization of novel polymers (19) (controlling release kinetics); and 
iii) developing new strategies for delivery (routes of administration). 
Another concern is related to production of particle technologies, particularly 
nano-sized technologies. With the exceptional growth and promise of particle 
technology, scale-up synthesis of these systems has been a manufacturing interest (20–
22). However, an often overseen yet vital aspect related to manufacturing is product 
purification. Prior to packaging and usage, drug products must be purified, to ensure 
the highest quality of the product (23). However, the purification of continuously 
manufactured and scaled-up batches of particle technologies has reached an impasse 
(24). Currently, the most often used purification method for particle technologies is 
centrifugation. Although this method is widely used and is highly regarded as an 
effective way to purify particle-based systems, there are major concerns with respect 
to scalability (23). Additionally, certain effects, such as the gravitational forces used in 
centrifuges, can have major impacts on the outcomes of NP characteristics (24). One 
potential solution is the usage of tangential flow filtration (TFF), which has quickly 
gained praise as a new method of scale-up purification for a variety of particle-based 
technologies (25–34). Unlike centrifugation, TFF utilizes fluid dynamics to decrease 
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the likelihood of aggregation by preventing gravitational force-related caking, while 
continually washing and concentrating NP suspensions (Figure 1.1) (23). This is 
achieved when fluid containing solutes flows tangentially to a replaceable filter. 
Despite its use and promise, there has not been an investigation on the key parameters 
of TFF to study the influence on NP characteristics. A study such as this would allow 
further understanding of TFF’s promise as a purification method as well as how the 
parameters impact the outcomes of NPs.  
 
Figure 1.1 Schematic representation of (a) dead end filtration (i.e. centrifugation) and 
(b) tangential flow filtration for separation of particulates (23). 
Polymers, which are the most often utilized type of drug carrier, continually 
present opportunities to advance particle-based technologies (2). The physical 
construction of polymers can be tuned and utilized to take advantage of passive 
targeting, to modify release kinetics, and to allow for targeting modification such as 
antibodies, small molecules, etc. (35, 36). In some cases, polymers can be naturally 
occurring or can be synthetic derivatives of natural polymers (biopolymers). Examples 
of biopolymers include chitosan, alginate, and peptides (36–39). Polysaccharides can 
also be utilized as drug carriers, often following chemical modification (19). From a 
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product standpoint, the use of polymers allows for the stable and robust production of 
drug carriers that can be tailored for both the patient population and the intended 
disease state.  
Acetalated dextran (Ac-Dex) is a synthetic derivative of dextran that was first 
synthesized a decade ago for drug delivery applications (40). Dextran, a water-soluble 
polysaccharide, is converted to water-insoluble Ac-Dex through a cost-effective, facile 
one-step reaction (Figure 1.2) (36, 40). The characteristics of Ac-Dex allow it to be a 
suitable polymer for the sustained delivery of therapeutic agents. The polymer is pH-
sensitive (acid labile), degrades into dextran and safe amounts of methanol and 
acetone, and is considered to be non-toxic, as seen in in vivo studies) (41, 42). In 
addition, Ac-Dex is tunable with respect to its degradation rate, where the influences 
of dextran molecular weight and reaction time impact the release kinetics of 
therapeutics loaded in Ac-Dex particle-based formulations. It has been shown in 
numerous studies that increases in both molecular weight and reaction time can slow 
release of encapsulated cargo (35, 43). The tunability of its degradation rate, combined 
with its acid-labile nature, make Ac-Dex an attractive polymer for triggered release at 
the site of cancer and infectious diseases, owing to their acidic microenvironments in 
addition to minimal release in circulation due to particle stability at physiological pH.   
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Figure 1.2. Reaction schematic of acetalated dextran. 
 
In total, Ac-Dex has been utilized in as many as 50 manuscripts, including an 
extensive review recently published in 2017 (19). Drug delivery technologies that 
have been created using Ac-Dex include porous microparticles, nanocomposite 
microparticles, nanoparticles, microconfetti, electrosprayed microparticles, 
nanocomposite microparticles and polymeric scaffolds (Figure 1.3) (19, 44, 45). 
Therapeutic cargos of both small and large molecular weights have been encapsulated 
in one or more of these systems and have been used for autoimmune diseases (42), 
vaccination (46–48), cancer (49, 50), infectious diseases (41, 51, 52), pulmonary 
diseases (53, 54), and tissue engineering (19).   
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Figure 1.3 Drug delivery technologies manufactured using Ac-Dex. Adopted from 
(19). 
 
Although Ac-Dex has shown promise as a versatile and cost-effective biopolymer, 
there are still knowledge gaps that require exploration. In this dissertation, research 
has been devoted to assessing the unexplored territories of Ac-Dex as a drug carrier to 
combat current drug delivery obstacles. In Manuscript 1, Ac-Dex nanoparticles (NP) 
were coated in phosphatidylserine (DPPS) to mimic apoptotic cells for active 
macrophage targeting. Following the synthesis and characterization of the DPPS-
coated NP, phospholipid coverage was confirmed using TEM and the Stewart’s assay. 
Finally, for biological confirmation, DPPS-coated NP were compared to DPPC/G-
coated NP and PVA-coated NP via their in vitro uptake into macrophages. In 
Manuscript 2, multiple types of Ac-Dex microparticles (MP) synthesized via spray 
drying were evaluated for their aerosol performance and were assessed for the release 
kinetic behavior of a water-soluble dye. Manuscript 3 evaluates a broader obstacle in 
particle technology. Using a design of experiment (DoE) approach, the effects of key 
parameters of tangential flow filtration (TFF) on the characteristics of Ac-Dex NP 
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were studied to understand the promise of TFF as a scale-up purification technique. 
The final manuscript evaluated the physical characteristics of Eact, followed by the 
development of Ac-Dex nanocomposite microparticles (nCmPs), to achieve deep lung 
deposition for the treatment of pulmonary arterial hypertension (PAH). In total, these 
manuscripts were designed and carried out with the intention of continuing the 
research devoted to Ac-Dex delivery formulations to provide further evidence that it is 
an efficient, versatile biopolymer for a variety of drug delivery applications. 
 
1.2 Significance of This Work  
The manuscripts in this dissertation are centered around the continued exploration 
of the biodegradable polymer Ac-Dex and its versatility as a drug carrier to overcome 
obstacles in drug delivery. The significance of this research is listed below. 
1. Ac-Dex nanoparticle systems can be tailored to actively target specific sites 
for diseases that would otherwise difficult to treat.  
2. Ac-Dex microparticle systems can be modified via facile tunability to 
modulate the drug release kinetics of payloads that are difficult to control.  
3. Ac-Dex nanoparticle systems can be purified using scale-up technology, 
allowing for large-scale production and more favorable nanoparticle 
characteristics, which can lead to increases in manufacturing efficiency.  
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1.3 Objectives of the Research  
The overall objective of this dissertation was to develop and characterize Ac-Dex 
particle-based technologies for drug delivery applications in order to explore and 
identify specific challenges that Ac-Dex can overcome, as well as explore boarder 
challenges for drug delivery to continue to show the versatility and promise of the 
biopolymer. In this regard, each manuscript has its own specific objectives:  
 
1. “Enhancement of Macrophage Uptake via Phosphatidylserine-Coated 
Acetalated Dextran Nanoparticles”: 
a. Prepare Ac-Dex nanoparticles (NP) loaded with a curcumin (CUR) for 
ease of quantification.  
b. Successfully coat Ac-Dex NP with phosphatidylserine (PS) and 
characterize the systems for their size, homogeneity, surface charge, 
and presence of coatings. 
c. Evaluate the drug release profiles of CUR-loaded PS NP at neutral and 
acidic pH.  
d. Evaluate the in vitro phagocytotic uptake of Ac-Dex PS NP into RAW 
264.7 murine macrophages.  
 
2. “Sustained Release of Water-Soluble Therapeutics via Dry Powder Aerosol 
Acetalated Dextran Microparticles” 
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a. Synthesize Ac-Dex microparticle (MP) systems encapsulating 
sulforhodamine B via various spray-drying conditions and two types of 
Ac-Dex (fast and slow degrading). 
b. Evaluate the physical and aerosol characteristics of the MP 
formulations.  
c. Examine the drug release profiles, and model the release kinetics of MP 
systems at neutral and acidic pH.  
d.  Examine biological interactions in vitro via cytotoxicity, uptake, and 
transepithelial electrical resistance studies.  
 
3.  “Comparison of Nanoparticle Purification Process via Centrifugation and 
Tangential Flow Filtration: A Case Study of Acetalated Dextran 
Nanoparticles” 
a. Utilize Design of Experiment to study key parameters of nanoparticles 
(NP) with respect to tangential flow filtration (TFF) purification.  
b. Compare properties of TFF-purified NP to centrifugation-purified NP. 
c. Evaluate the variability in NP characteristics following purification by 
TFF when varying small molecules are encapsulated in NP systems.  
 
4.  “Physical Characterization and Formulation Development of Eact for the 
Treatment of Pulmonary Arterial Hypertension” 
a. Physical characterization of Eact. 
b. Synthesis and characterization of Eact-loaded nanoparticles. 
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c. Synthesis of Eact nCmP via spray drying, and evaluation of physical 
characteristics and aerosol performance of nCmP formulations.  
 
1.4 Organization of Dissertation  
The remainder of this dissertation will be organized as follows:  
Chapter 2 provides a background on particle-based technology, as well as 
parenteral delivery and pulmonary routes of administration. The latter two sections 
(routes of administration) are partially adopted from Chapter 6 of the book 
“Nanoparticles for Biomedical Applications” (55), which is currently under review for 
publication.  
Chapter 3 describes the work related to the manuscript, “Enhancement of 
Macrophage Uptake via Phosphatidylserine-Coated Acetalated Dextran 
Nanoparticles” (52), which involves the design and development of phospholipid-
coated Ac-Dex nanoparticles capable of actively targeting and being uptake by 
macrophages.  
Chapter 4 describes the work related to the manuscript, “Sustained Release of 
Water-Soluble Therapeutics via Dry Powder Aerosol Acetalated Dextran 
Microparticles,” which involves the synthesis of Ac-Dex microparticles via spray 
drying, and the observation of their drug release behaviors and aerosol performance.  
Chapter 5 describes the work related to the manuscript, “Comparison of 
Nanoparticle Purification Process via Centrifugation and Tangential Flow Filtration: A 
Case Study of Acetalated Dextran Nanoparticles,” which involves the use of Design of 
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Experiments to identify and study the effects of key tangential flow filtration 
parameters (factors) on Ac-Dex nanoparticle characteristics (responses).   
Chapter 6 presents data related to the “Physical Characterization and Formulation 
Development of Eact for the Treatment of Pulmonary Arterial Hypertension,” which 
involves the design and characterization of nanocomposite microparticles 
encapsulating Eact, a small molecule currently under investigation for its therapeutic 
potential for treating pulmonary arterial hypertension.  
Chapter 7 concludes the dissertation and addresses future problems and future 
directions of Ac-Dex-based drug delivery formulations.  
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2.1 Particle Technology  
 The use of particle-based technologies have significantly advanced the fields 
of electronics, food, industrial development, and medicine (56). Within the medical 
field, particle technologies have made enormous strides as diagnostic and therapeutic 
agents, and therapeutic delivery systems. Through particle engineering, particle-based 
technologies exhibiting specific size, shape, surface charge, and physicochemical 
characteristics can be developed for a variety of disease states or imaging techniques 
(57).  
Microparticles (MP) are used for depot injections, as inhalable powders, and as 
therapeutic agents. Depot injections such as Risperdal Consta® and Invega Trinza® 
have shown great success in treating patients with mental health disorders, including 
schizophrenia and bipolar disorder (58, 59). Additionally, formulations for depot 
injections have been approved for treating diseases such as cancer and alcohol 
dependence (59). Dry powder aerosols are a type of MP intended for pulmonary 
administration to treat numerous diseases. TOBI® Podhaler™ is an example of a dry 
powder aerosol formulation that is used for the treatment of cystic fibrosis-related 
infections (60). Through the usage of PulmoSphere™ technology, dry powder 
aerosols take the form of spherical, porous MP, allowing for effective delivery (61). 
MP have also shown success as therapeutic agents. One example is Sebacia 
Microparticles® for the treatment of acne, which was approved for clinical use in 2018 
(62). Following topical administration of a suspension, gold-coated silica MP are 
heated with a laser, which  induces thermal injury to the targeted sites without 
inducing a major inflammatory response (63). Another example is Yttirum-90 
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microspheres, which have been explored as a possible alternative approach for cancer 
treatment (64). 
Nanoparticles (NP) range from 1 nm to under 1 micron. These systems are 
often used as drug delivery systems, therapeutics, and diagnostic tools. As of 2016, a 
total of 13 products including liposomal (Doxil®), nanocrystal (Rapamune®), 
polymeric (Copaxone®), albumin-bound nanoparticle (Abraxane®), and inorganic 
(Feraheme®) formulations have been approved for use by the FDA as NP-based 
systems for therapeutic purposes (1, 65, 66). From 2013 to 2016 the number of clinical 
trials involving nanotechnology has increased 3-fold and it is anticipated that this 
trend will continue, with an overall increase in FDA approvals (1). Thus far, all FDA 
approved nano-based technologies have been “simple” (NP core plus a coating) and 
have been based on usage of biological processes and endogenous phenomena for 
particle uptake and deposition. However, since nanotechnology continues to build 
from previous successes and failures, it is likely that more complex formulations 
(external stimuli, active targeting via ligands and antibodies, etc.) will soon be in 
clinical trials (1).  
Although particle technology has existed for a substantial amount of time, 
there is still a tremendous amount of funding and research devoted to designing and 
developing technologies for the treatment and diagnosis of numerous disease states 
(65).  Included in their design are ideologies of the specific routes of administration 
that may be used for delivery (57). In general, particle-based technologies have been 
explored in almost every administration route, with parenteral routes being the most 
common (1). However, the pulmonary route is gaining more interest due the ability to 
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localize delivery, increase compliance, and increase treatment efficacy, while 
decreasing both drug metabolism and systemic side effects. The following sections 
below, partially adopted from the book “Nanoparticles for Biomedical Applications” 
describe both parenteral and pulmonary routes of administration for particle-based 
technologies that pertain to this dissertation.  
 
2.2 Parenteral Delivery  
Parenteral delivery is the administration of a therapeutic that goes through 
biological tissues directly to blood vessels, organs, or tissues (67, 68). This type of 
delivery offers advantages including high bioavailability, and in some cases, 
exceptional therapeutic absorption (68, 69). This method can be utilized for patients 
who cannot take oral formulations due to limitations (e.g. sickness, obstruction, loss of 
consciousness, etc.). These routes of administration are often favorable for patients 
experiencing disease states that require immediate therapy, and for drug monitoring by 
medical personnel (68, 70–73). The types of parenteral delivery routes that will be 
discussed in this chapter include intravenous, intramuscular, intraperitoneal, and 
subcutaneous routes (Figure 2.1A).  
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Figure 2.1 (A) Routes and delivery locations for parenteral delivery of therapeutics or 
nanocarriers, including intramuscular, subcutaneous, intravenous, and intradermal 
delivery methods. (B) Cellular and non-cellular pulmonary barriers for nanocarriers 
including those present in the central lung/upper airways (bronchial) and 
peripheral/lower airways (alveoli). Adapted from (74) and (75). 
 
2.2.1 Intravenous Delivery  
Aside from oral administration, intravenous (IV) delivery is the most 
commonly used route of administration in the clinic and involves the delivery of 
nanocarriers into veins (1). Dosing is performed using either bolus or infusion 
delivery. The fate of IV-delivered nanocarriers is based on the physical makeup of the 
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product (active ingredient and excipients). Alterations to the product and its 
characteristics will determine overall outcomes. Products administered by IV 
administration are subject to numerous biological challenges that stem from their 
physical characteristics including size, charge, shape, and surface modifications (57, 
76). Within the body, nanocarriers are subject to protein adsorption, rapid elimination 
by the reticuloendothelial system (RES), unwanted tissue deposition, and restricted 
access by biological barriers (68, 77, 78). Size plays a key role in the biological 
elimination of nanocarriers, where carriers < 10 nm are small enough to be filtered and 
cleared by renal clearance, whereas carriers > 200 nm are susceptible to the RES, 
leading to a decrease in therapy (78). Charge also plays a key role in the interactions 
of nanocarriers with circulating proteins and phagocytotic cells (79, 80). Highly 
negative carriers are susceptible to macrophage uptake, whereas positively-charged 
products are likely to aggregate with circulation proteins and cellular membranes and 
are often toxic. Therefore, neutrally-charged formulations are usually overall 
favorable, unless a specific biological action utilizing charge is desired (i.e. 
macrophage uptake) (57, 79, 80). Surface modifications will also have a significant 
impact on the biological end-point of nanocarriers (57, 81, 82). Numerous studies have 
shown unfavorable pharmacokinetic (PK) profiles and unwanted deposition based on 
the lack of targeting or other forms of modification (77, 78, 83). Although there is 
evidence to support nanocarrier shape plays a role in biological interactions, research 
is still ongoing (84). 
The major advantage of IV administration is based on the direct delivery of 
products into circulation (70), which allows for increased bioavailability. In 
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comparison to IV delivery, orally-administered carriers are exposed to enzymes that 
cause degradation of drugs, acidic pH, and mucus. IV administration of products 
avoids complications related to degradation, allowing for more effective delivery of 
sensitive carriers (69, 70). In addition, IV delivery is advantageous for carriers that 
require careful drug monitoring (68, 77, 85). 
 
2.2.1.1 Applications 
Finding ways to predict biological outcomes of nanocarriers in vitro has been a 
subject of interest for many years. For example, one study investigated the interactions 
of nanocarriers and blood components and showed a simple yet detailed method to 
measure the influence of protein adsorption, coagulation, complement activation, and 
hemolysis on nanocarrier characteristics (76). Another study utilized centrifugation as 
a method to examine cellular membrane binding and disruption in the characteristics 
of nanocarriers (86). The development of in vitro experiments such as these can 
provide time and cost-efficient ways to predict outcomes of nanocarriers in vivo. In 
addition, research on the impact of surface modification of nanocarriers has been a 
subject of interest in order to increase the targetability of nanocarriers, to increase 
pharmacokinetic profiles and decrease side effects. The most successful modification 
to date is antibody (Ab) conjugation, and clinical trials exploring Ab-functionalized 
nanocarriers are underway (77).  
Both polymeric and liposomal nanocarriers used for chemotherapy have had 
some success in the clinic and are primarily administered via IV, and the majority of 
FDA-approved liposomal formulations are administered via IV (87). Improvement of 
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PK profiles compared to drug suspensions and a decrease in toxicity have been major 
advantages of chemotherapeutic nanocarriers (68). Furthermore, the enhanced 
permeability and retention (EPR) effect is another benefit of IV administration. The 
proposed mechanism is based on “leaky” blood vessels present in and around tumors, 
which allow for nanosized material to more readily reach the tumor tissue and exert 
their therapeutic action (71, 77, 85, 88). To facilitate EPR, nanocarriers are often 
coated with a hydrophilic, neutral polymer that can allow the nanocarrier avoiding 
protein aggregation on the surface of the carrier, reducing clearance in the RES (1, 8, 
85). Poly(ethylene glycol) (PEG) is the most widely used hydrophilic polymer for 
nanoparticle coatings (78, 83) and PEG coatings are used in several FDA-approved 
nanomedicine formulations (e.g. Doxil®) (8, 87). Another FDA-approved cancer 
nanocarrier formulation is Abraxane®, a third-generation paclitaxel (PTX) delivery 
formulation that consists of PTX bound to human serum albumin, the most common 
circulation protein (71, 87). Abraxane® has shown significant improvements in 
administration time (decrease from 3 hours to 30 minutes), as well as improvements in 
critical PK characteristics in comparison to Taxol®, the commonly used PTX 
formulation (71).  
 
2.2.1.2 Obstacles and Applications  
IV administration is one of the most-widely used administration routes and the 
main administration route for anti-cancer therapeutics (71, 77, 88). Despite widespread 
studies investigating colloidal science and biological interactions (76, 86, 89), more 
studies are needed to further identify and counter potential hazards of IV-delivered 
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nanocarriers. Other obstacles to consider are more technical. Scale-up synthesis and 
high-throughput screening methods need to be designed to combat the issue of supply 
and time-cost investment. An example of this includes product shortage such as the 
current Doxil® shortage, which needs to be avoided (77). Based on the major 
obstacles, there are plenty of opportunities for the design of high-throughput screening 
methods, scale up manufacturing, and predictive tools.  
 
2.2.3 Intraperitoneal Delivery  
Intraperitoneal (IP) delivery involves the delivery of therapeutics to the 
peritoneum cavity to increase local concentrations (90). The major use of IP delivery 
has been for the treatment of peritoneal cancers. The fate of nanocarriers administered 
via the IP route is highly dependent on the localization of the malignant tissue and the 
deposition of the administered product in relation to vital organs (91). IP 
administration generally during or post-surgery (92) and deposition of nanocarriers are 
initially localized at the administration site, while deviation from the site is affected by 
the physical characteristics and surface modifications of the formulation, and the 
dynamics of the site itself including fluid dynamics, gravity, presence of mucus, etc. 
(93).  
In addition to avoiding the stomach, intestines, and first-pass metabolism, the 
major advantage of IP delivery is the superior level of treatment over IV 
administration, likely due to the close proximity of therapeutics to malignant tissue 
(92). IP delivery has been used in the clinic for over 50 years and has demonstrated 
that it is very efficient in destroying cancerous tissue post-surgery (94). Also, IP 
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administration results in reduced levels of systemic exposure (91, 94, 95). Although IP 
administration of nanocarriers offer several advantages, challenges are inevitable. 
Major challenges are the side effects associated with IP delivery, including pain, 
discomfort, and systemic toxicity (96). While side effects such as pain and discomfort 
are likely unavoidable, systemic toxicity needs to be addressed by designing 
nanocarriers that can remain localized. Also, traditional chemotherapeutics are subject 
to short residence times and require frequent or continuous administration, which can 
increase side effects and the likelihood of toxicity (94, 96, 97). 
 
2.2.3.1 Applications, Obstacles, and Opportunities 
To address some of challenges pertaining to IP administration, the 
development of formulations to improve the localization of IP therapeutics is a 
promising approach. One such method is the development of adhesive formulations 
that can adhere to the peritoneum, such as chitosan-coated nanocarriers (97). Another 
method would be the inclusion of nanocarriers in biological mimics, such as hydrogels 
(94, 96). Nanocarriers with targeting ligands, that includes antibodies and peptides, are 
also being explored (90, 98, 99) and formulations that exhibit controlled release have 
also shown promise as novel approaches (94). Another approach that can be used to 
complement currently-used clinical treatments include nanocarrier-driven 
hyperthermic intraperitoneal chemotherapy (HIPEC), and pressurized intraperitoneal 
aerosol chemotherapy (PIPAC). Traditional HIPEC involves the administration of pre-
heated chemotherapeutic solution to a site of interest (92). In doing so, the increased 
temperature allows for increased drug penetration and therapeutic efficacy (90, 93, 
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99). Clinically, HIPEC has shown to increase the survival rate when used in 
conjunction with surgery (100). PIPAC, a newer treatment option, utilizes the 
nebulization of therapeutic solutions (both raw drug and formulations) using CO2 (93, 
99, 101). To assist in both HIPEC and PIPAC, nanocarriers can be used to control 
solution and tissue heating, and increase drug deposition via passive and active 
targeting (93, 99, 101, 102). As of 2017, nanoparticle formulations developed for the 
treatment of IP-related cancers are in clinical trials (93). A phase I study of IP-
administered formulated paclitaxel (Nanotox®) showed higher and prolonged drug 
levels within the peritoneum, resulting in minimal toxicity and systemic drug exposure 
following six doses of Nanotax® administered for six cycles (95). A form of HIPEC 
that utilizes nanocarriers through the use of external heating of inorganic materials to 
enhance delivery and penetration is currently being studied as well (99, 103). In 
addition, bio-adhesive systems such as hydrogels and nanocarriers have also shown 
promise to increase the residence time of therapeutics and decrease nanoparticle 
clearance from the peritoneum (94, 96, 97). 
 
2.2.4 Intramuscular Delivery  
Intramuscular (IM) administration involves the delivery of a therapeutic within 
a muscle and is the most common route used for the delivery of vaccines (104). In 
addition, IM delivery is often explored as a route for depot products such as hydrogels 
and microspheres (105, 106). The deposition of IM-administered products is heavily 
dependent on the overall immune response at the delivery site. With respect to the use 
of IM delivery for vaccines, immune responses are preferred (107, 108). However, an 
 23 
 
immune response following administration of formulations that result in the extended 
release of small molecules is undesirable. Inflammation can result in the recruitment 
of various white blood cells, which can pose a threat to small molecule formulations, 
as they would be recognized as foreign objects and would be engulfed (109).  
Like most parenteral delivery systems, invasiveness, pain, and stress are major 
drawbacks for IM delivery. Additionally, IM administration can be associated with 
severe pain, immune responses (rashes, erythema, inflammation, etc.), and in severe 
cases, tissue necrosis (110). In most cases, acute edema (swelling) at the site of 
injection occurs. Due to the interest in long-acting injectables with IM being the 
preferred route, attention needs to be paid to ensure that prolonged and stable release 
is achieved for the desired time (106, 110). Generally, the major challenge with IM 
delivery lies in water-soluble therapeutics, which can result in challenges in 
dissolution, degradation, and uptake of both the therapeutic and the formulation (109). 
IM injection of microspheres and hydrogels is a viable alternative to the oral delivery 
of certain therapeutics, thereby increasing the overall PK and dynamic profiles of the 
therapeutics, while decreasing the likelihood of systemic side effects (67, 111). 
Additionally, IM-administered depot injections can allow for the modulation of dosing 
regimens by decreasing the dosing frequency.  
 
2.2.4.1 Applications, Obstacles, and Opportunities 
Although there are drawbacks concerning patient compliance and biological 
responses with IM delivery, vaccine and biological therapeutic research is heavily 
dependent on this type of delivery (108, 109). As a result, a significant portion of IM 
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delivery-related research is devoted to improving the sustained release and biological 
responses of newly developed vaccines and other biological therapeutics (107, 112). 
This interest is mainly due to the advantageous changes in PK and dynamic profiles of 
nanocarrier formulations, as well as the significant decrease in dosing frequency (67, 
106, 111). Another novel use of nanocarriers in IM delivery is the development of 
adjuvants, which are entities that work to increase antigen uptake and promote 
dendritic cells to initiate an immune response (113). Aside from vaccine products, 
there are very few products using IM for the delivery of small molecules. 
Microspheres are the main form of technology used for sustained drug release for 
these applications (106, 111). Currently, there are no FDA-approved nanoscale IM 
formulations and the future of IM delivery is dependent on extending the time between 
doses of both small and large molecule therapeutics.  
 
2.2.5 Subcutaneous Delivery 
Subcutaneous (SC) administration involves the delivery of therapeutics into the 
interstitial area underlying the epidermis via injection. The interstitial area under the 
skin is primarily comprised of negatively-charged glycosaminoglycan and collagen 
fibers, which provides a relatively slow and steady absorption rate of molecules, 
owing to reduced blood flow (114). Conventional SC formulations include aqueous 
solutions, oily solutions, suspensions, and simple emulsions of therapeutics. In order 
to modify the release profile of compounds, they can be encapsulated into particle or 
implant-based formulations. Particle-based delivery systems can also be applied for 
lymph-targeting delivery (115). 
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The fate of nanocarriers delivered through the SC route depends on the particle 
properties and the injection location (116). Particle size is the key factor in 
determining the final absorption route. Particles < 10 nm tend to be absorbed via the 
capillaries draining from the injection site, where they then go into systemic 
circulation. Particles 10-100 nm in diameter move through the interstitium and are 
taken up directly into the lymphatic system. Particles > 100 nm show low capability of 
diffusion through the water channel within the interstitium (also around 100 nm). As a 
result, the larger particles mostly retain at the injection site and form a depot. During 
particle diffusion through interstitium, charge and hydrophilicity play important roles 
as they influence the interaction between particles and interstitial compounds. 
Furthermore, the driving force of particle transport into lymph is fluid flow from the 
interstitium to the lymphatics, which varies in different locations. Correspondingly, 
the variation of injection site also affects the lymphatic transport by changing the fluid 
flow and pressure surrounding the formulation (116–119). 
 
2.2.5.1 Applications and Advantages 
SC administration of therapeutics is widely applied to obtain higher 
bioavailability, to modify the release profile to allow for longer systemic exposure, or 
to serve as an alternative dosing route when oral delivery is not applicable (115). 
Various nanocarrier-based SC formulations have been developed to deliver 
therapeutics such anti-cancer drugs (118), antibiotics (106), HIV drugs (120), peptide 
hormones (121), anticoagulants (122), protein drugs (123), mRNA (124), and 
immunosuppressive anti-rheumatic drugs (125). Such nanocarrier-based formulations 
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have been developed for the treatment of pancreatic, non-small cell lung, breast, 
ovarian cancers (118), gastrointestinal clostridium difficile-associated diseases (106), 
tuberculosis (126), lymphatic filariasis (116), venous thrombosis (122), inflammatory 
diseases (123), rheumatoid arthritis (125), and the prevention of HIV-1 vaginal 
transmission (1). The function of these particular nanocarriers can be divided into 
three aspects, including 1) the formation of depots at the injection site in order to 
provide sustained release of therapeutics (106, 118, 120–122, 125, 126), 2) the 
application of particles 70-110 nm in diameter for lymphatic system targeting (116, 
125), or 3) systemic delivery of nanocarriers via the SC route (124). 
Compared to other parenteral routes such as IV and IM administration, SC 
administration is typically convenient to patients. First, it is often less painful and less 
time consuming, which improves patient compliance. Furthermore, it is easy to do and 
suitable for self-administration, which reduces the total cost of treatment (119, 127). In 
addition, nanocarrier formulations delivered via the SC route provide protection for 
the therapeutic and result in prolonged release, thereby reducing dosing frequency, 
improved safety and efficiency, and targeted delivery of therapeutics (116).  
 
2.3 Pulmonary Delivery  
In recent years, pulmonary delivery has been a growing interest owing to its 
advantages over other delivery systems to treat local diseases in the lungs and 
respiratory tract such as asthma, infectious diseases, cancer, and chronic obstructive 
pulmonary diseases (COPD) (128). Local administration to the lungs provides high 
concentration of a drug at the site of action, lowering the overall dose required, 
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thereby reducing systemic side effects (129, 130). Due to the high surface area in the 
lungs (75-140 m2 in total), systemic delivery can be attained via the alveoli, where the 
drug can be absorbed into the bloodstream (131–133). Absorption by the alveoli 
allows for a rapid onset of action and avoidance of first-pass metabolism (134, 135).  
 
2.3.1 Delivery Devices 
The three major types of inhalers used for pulmonary delivery are metered 
dose inhalers (MDIs), nebulizers, and dry powder inhalers (DPIs) (136, 137). The 
mechanisms of delivery and the formulation requirements differ by the type of inhaler 
used. MDIs are pressurized vessels that rely on the driving force of the propellant to 
atomize droplets containing drug(s) and excipients, where the drugs are either 
solutions or particulate suspensions (136, 138). Nebulizers deliver liquid drug 
formulations in a steady stream of droplets of 1-5 µm, and can deliver larger doses 
compared to other inhalers, but may also require longer dosage times (139). 
Nebulizers produce ultra-fine droplets with high polydispersity, which can make them 
unsuitable for the delivery of larger particles (bigger than the droplet size) (131). Dry 
powder inhalers (DPIs) are breath-activated devices that deliver therapeutics in the 
form of a dry powder directly to the airways. During administration, a capsule 
containing a set dose of drug is punctured and the drug is aerosolized (140). 
Therapeutics delivered using DPIs tend to agglomerate due to hygroscopic phenomena 
and electrostatic interactions, which reduce aerosolization performance (131). DPIs 
can be preferred over other devices owing to the promise of physical stability of the 
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formulation in solid form, ease to use and transportation, and application to variety of 
active ingredients and dose weights (141, 142).  
 
2.3.2 Particle Fate 
Particle deposition in the lungs is governed by the aerodynamic diameter of the 
particles and occurs by one of three mechanisms: inertial impaction, sedimentation, or 
diffusion. Additionally, inhalable particles can be categorized into different sizes, 
including coarse (≥ 5 μm), fine (0.5–5 μm), or ultrafine (≤ 0.5 μm) (133). Coarse 
carriers collide with the upper airways (trachea and large bronchi) and deposit by 
impaction, fine particles can reach the lower lung airways by sedimentation, and 
ultrafine particles can deposit throughout the respiratory tract, reaching the alveoli by 
diffusion (132, 133). Particles within the fine and ultrafine categories fall in the 1 – 5 
μm range of values for deposition by sedimentation (45).  
 
2.3.2.1 Microparticles 
 Inhalable microparticles (MP) can be categorized as coarse or fine particles. 
While MP are exceptionally larger than nanoparticles (NP), properly engineered MP 
are able to reach deeper regions of the lungs (45, 143). In most cases, particles in the 
micron range deposit via impaction or sedimentation (133). While spherical particles 
are the most recognized systems, porous and corrugate particles have shown 
exceptional results and promise for pulmonary administration (144). Although porous 
MP are inherently large in geometric size (coarse size range), the aerodynamic 
diameters are low, while the internal pores allow for low mass density and high 
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surface area (144, 145). The characteristics allow for the avoidance of macrophage 
uptake, while achieving favorable aerodynamic and drug release performances (49). 
Corrugated morphology allows for deeper lung delivery in comparison to spherical 
morphology particles. This is likely linked to the inherent decreases in particle 
cohesion and smaller aerodynamic diameter, as a result of the corrugations (145, 146).  
 
2.3.2.2 Nanoparticles 
 Nanoparticles (NP) fall within the range of fine or ultrafine inhalable particles. 
Through utilization of their size, NP are able to deposit in the lower areas of the lungs, 
via Brownian diffusion, and are able to reach the alveoli (133). Additionally, NP offer 
an increase in surface area to volume ratio, which enhances the solubility and 
dissolution rate of poorly water-soluble drugs. Deposition into the alveoli as well as 
the increased dissolution rate promotes increased absorption, allowing for increases in 
overall bioavailability (130, 137, 147). However, it should be noted that these 
particles, due to their size and density, are likely to be exhaled (133). To bypass this 
challenge, Nebulizers, MDI, and DPI can be used to generate aerosols (131, 133, 139, 
141, 142). Another method to overcome this challenge is through the design of 
nanocomposite microparticle (nCmP) systems. By forming aggregates of NP, nCmP 
are able to utilize the advantages presented with corrugated MP structures (44). As NP 
aggregate, they form a MP-like structure, increasing the inherent size of the system. 
Upon initial inhalation, nCmP are able to stay in their MP-like structure. Once nCmP 
reach fluid in the lungs, they dissociate to NP  and deposit further into the lungs (54).  
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2.3.3 Advantages and Applications 
Oral and IV administration are the two most common methods of therapeutic 
delivery (1). However, due to systemic exposure, therapeutics that demonstrate a small 
therapeutic window and/or are potent are likely to be associated with side effects 
and/or toxicity. Administration of particle-based delivery systems via inhalation can 
limit systemic exposure, thereby decreasing overall side effects (130). Pulmonary 
administration allows for localized delivery of therapeutics. For example, diseases 
such as tuberculosis and lung cancer are treated with potent drugs via extended dosing 
regimens, often via IV administration (148–150). Localized administration can 
decrease such regimens while altering the administration route, thereby increasing 
overall patient compliance (148). Complimenting this is the potential for increased 
treatment efficacy, as localized delivery can promote increased drug exposure to sites 
of interest. The other major advantage of pulmonary administration is the potential for 
increased bioavailability via increased absorption and bypassing of first-pass 
metabolism (44, 130, 147). The combination of a thin epithelial monolayer, high 
vascularization, and high surface area of the alveoli can allow administered 
therapeutics to diffuse into the bloodstream, promoting high absorption rates and rapid 
onsets of action (133). Additionally, the lungs have minimal enzymatic activity, 
limiting the amount of drug metabolism that occurs (130).  
The advantages provided by pulmonary administration promote improved 
treatment options for diseases such as cystic fibrosis, lung cancer, pulmonary 
hypertension, and other disease states that can have severe impacts on both the 
pulmonary system, and the patient (129, 151, 152). Additionally, due to the limited 
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enzymatic activity in the lungs, delivery of macromolecules via inhalation is another 
major research interest (130). Bypassing IV administration via pulmonary 
administration for macromolecule agents (vaccines, peptides, etc.) can greatly increase 
patient compliance of such entities (145). An example of a successful pulmonary drug 
delivery system is TOBI® Podhaler™, a dry powder dosage form of tobramycin 
developed for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis 
patients (60, 153).  
 
2.3.4 Challenges 
Like other particle-based delivery systems, interactions with biological entities 
in the lungs can be an issue. Interactions among mucus, bronchial epithelium tissue, 
and alveolar macrophages all present significant challenges for pulmonary 
administered systems (129). Mucus presents a major challenge due to its viscoelastic 
properties and physical structure (154–156). Mucociliary clearance generally occurs in 
the upper airways of the lungs, where foreign material is lodged and entrapped in the 
mucus (154–156). Clearance then occurs when cilia transport this mixture to 
coordinate a coughing or swallowing response (157). Bronchial epithelium tissues, 
like other epithelial tissues, are inherently lipophilic with tight junctions (limiting 
passive paracellular transport), and contain both uptake and efflux transporters (158, 
159). Although uptake transporters can promote drug absorption, efflux transporters 
will demote it. Alveolar macrophages in the lower airways are capable of 
phagocytosing foreign materials, including particle-based delivery systems that are 
approximately a few micron or less in diameter (160). A diagram of potential 
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biological barriers can be seen in Figure 2.1B. To avoid these major barriers, particle-
based delivery systems need to be carefully designed and tailored to bypassing 
specific challenges.  
 
2.3.5 Future Opportunities 
 Present challenges and the growth of biological therapeutics have both created 
continual opportunities for pulmonary administration of particle-based delivery 
systems. It is important to note that fundamental characteristics including particle size, 
morphology, and surface charge can also provide options to bypass challenges faced in 
pulmonary delivery (133, 145, 161, 162). The importance of size is highlighted in 
sections 2.3.2.1 and 2.3.2.2. Surface morphology plays a significant role in the 
deposition of particles, particularly for MPs, and is highlighted in section 2.3.2.1. In 
terms of surface charge, neutrally charged systems show the highest promise for 
pulmonary administration (54, 163). While cationic surfaces can increase cell toxicity, 
and negative surfaces can increase alveolar macrophage uptake, functionally neutral 
surfaces have shown exception promise in avoiding macrophage uptake, as well as 
increased mucus diffusion (163–166).  
A major research interest for pulmonary delivery systems is the particle 
engineering of systems that can readily diffuse through mucus for the treatment of 
multiple disease states (167–170). Bypassing of the mucus to increase the treatment of 
bacterial diseases, especially those associated with cystic fibrosis stands as an 
exceptionally interesting research topic currently (155, 171, 172). Another research 
interest is the understanding of transport phenomena across epithelial tissue. Although 
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a newer point of interest, results from numerous studies show that particle systems, 
particularly NP, utilize a multitude of diffusion methods to cross epithelial tissue, 
warranting more research to be devoted to understanding these phenomena and 
possible explanations (6).   
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3.1 Abstract 
Although vital to the body’s immune system, macrophages can also act as 
reservoirs for pathogens from infectious diseases such as tuberculosis and the human 
immunodeficiency virus. Limitations in the treatment of such diseases include the 
challenge of targeting therapeutics directly to the macrophages and the large systemic 
dosages often needed for treatment. The objective of the present study is to develop a 
nanoparticle (NP)-based drug delivery system that can more effectively deliver 
therapeutic agents into macrophages. Acetalated dextran (Ac-Dex) NP loaded with the 
lipophilic model compound curcumin (CUR) were synthesized and coated in 1,2-
dipalmitoyl-sn-glycero-3-phospho-L-serine (DPPS), a phospholipid that induces 
phagocytosis in macrophages. DPPS-CUR NP were found to release 67.8% of 
encapsulated CUR within 24 hours at pH 5.35 and exhibited minimal CUR release 
(6.3%) at pH 7.4. DPPS-CUR NP were uptaken by murine macrophages significantly 
more than NP without DPPS coating and NP exposure to these macrophages resulted 
in minimal toxicity to the cells and minimal nitric oxide production. These results 
suggest that the combination of the DPPS coating and pH-sensitive polymer Ac-Dex 
can provide a NP delivery system capable of enhanced uptake by macrophages and 
potential systemic stability to more effectively deliver drugs of interest. As a result, 
the described DPPS-CUR NP can serve as a viable delivery system for the treatment 
of macrophage-associated diseases.  
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3.2 Keywords  
Acetalated dextran; 1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine (DPPS); 
macrophage-associated diseases; targeted cellular uptake; nanoparticles; drug delivery 
 
3.3 Abbreviations  
2-methoxypropene (2-MOP), acetalated dextran (Ac-Dex), curcumin (CUR), cyclic-
to-acyclic ration (CAC),  dichloromethane (DCM), dimethyl sulfoxide (DMSO), 
deionized (DI) water, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-
dipalmitoyl-sn-glycero-3-phospho(1’-rac’glycerol) (DPPG), 1,2-dipalmitoyl-sn-
glycero-3-phospho-L-serine (DPPS), differential scanning calorimetry (DSC), 
encapsulation efficiency (EE), human immunodeficiency virus (HIV), 
lipopolysaccharide (LPS), nitric oxide (NO), nanoparticles (NP), phosphate buffered 
saline (PBS), phosphatidylserine (PS), poly(vinyl alcohol) (PVA), poly(lactic-co-
glycolic acid) (PLGA), p-toluenesulfonate (PPTS), scanning electron microscopy 
(SEM), tuberculosis (TB), transmission electron microscopy (TEM), triethylamine 
(TEA) 
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3.4 Introduction 
Macrophages are vital in the removal of cellular debris and foreign bodies to 
maintain homeostasis in the human body (82, 173), can colonize in the liver, lungs, 
spleen, lymph nodes, marrow, or brain, and are critical to the innate immune system 
(173). An example of the importance of macrophages is in the removal of apoptotic 
cells via stimulation of various signals and markers that are overexpressed by 
presenting cells to initiate identification and engulfment (174). Although macrophages 
are involved in the protection and maintenance of the human body, there are scenarios 
in which these cells can result in more harm than good. Macrophages have the 
potential to act as reservoirs for infectious pathogens, including those related to two of 
the most prevalent infectious diseases, tuberculosis (TB) (82, 173) and the human 
immunodeficiency virus (HIV) (82, 173). The commonality amongst these diseases 
lies in the extensive treatment times and dosing regimens necessary to treat TB and 
HIV, often resulting in negative side effects. As a result, treatment by way of 
enhanced delivery to macrophages is of growing interest (10, 43, 180–186, 82, 173–
179). 
Recent progress in the development of macrophage targeting systems have 
been based around receptor-ligand interactions (187). One common approach is 
surface functionalization of systems with mannose residues to target CD206 (mannose 
receptor), a carbohydrate-recognition domain that is largely expressed on alveolar 
macrophages (188, 189). In other cases, tumor associated macrophages can also be 
targeted using peptide-based ligands such as rabies virus glycoprotein (RVG), and can 
be used as carriers for systems encapsulating anti-cancer therapies (190, 191). Other 
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ligands such as 4-SO4-GalNAc can be used to target other receptors on the surface of 
phagocytic macrophages to increase targeted uptake (192).  
Phosphatidylserine (PS) is an anionic phospholipid that is produced and 
stationed on the inner membrane of healthy cells (174, 181, 193, 194). Once apoptosis 
is induced, PS transitions from the inner leaflet to the outer leaflet of the cell 
membrane (178). Apoptotic cells produce a signal via PS exposure to stimulate the 
attraction of macrophages for engulfment of the presenting cells (phagocytosis) via 
receptor-ligand interactions or identification of PS binding proteins produced by 
phagocytes (82, 174, 194, 195). Although it is essential for the phagocytosis signal, 
there is some debate as to whether sole exposure of PS is sufficient to induce the 
uptake of apoptotic cells by macrophages in vitro (174, 194, 195). However, particle-
based drug delivery systems that utilize PS (specifically, 1,2-dipalmitoyl-sn-glycero-3-
phospho-L-serine, DPPS) as the particle coating have resulted in enhanced 
macrophage uptake through the sole presence of PS (174), likely due to the amount of 
PS presented. Multiple studies centered around treatment of inflammation (183, 196), 
HIV-1 (82, 173, 180, 182), cancer (184, 185, 197), atherosclerosis (198), and MRI 
imaging (10, 82, 175) have used DPPS coatings to increase the uptake of particle-
based delivery systems by macrophages or have used PS as a binding target.  
Acetalated dextran (Ac-Dex) is a biodegradable, biocompatible polymer 
comprised of the FDA-approved excipient dextran and hydrophobic acetal groups that 
allow for emulsion-based NP synthesis (19, 45, 53). Unlike commonly used drug 
carriers such as poly(lactic-co-glycolic acid) (PLGA), the degradation kinetics of Ac-
Dex can be easily tuned by altering the ratio of cyclic to acyclic acetal groups by 
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modifying the Ac-Dex synthesis reaction time (36, 40). The acid-sensitivity of Ac-Dex 
has made it a viable carrier option in applications for cancer (36, 40, 49), 
inflammatory-related conditions (42), vaccines (36, 40), and antibiotic delivery (54). 
There is a significant difference in degradation and drug release kinetics for Ac-Dex 
nanoparticle (NP) systems at a pH of 5 (faster release) versus at a pH of 7.4 (slower 
release) (36, 40, 42, 43, 45, 49, 53, 54). Due to this difference, Ac-Dex NP systems 
will exhibit slower release and stability during systemic circulation (at pH 7.4) until 
they are delivered to a site in the body with a lower pH, such as in macrophages, 
where therapeutics will be readily released. 
 The current study involves the design of a novel therapeutic particle-based 
drug delivery system consisting of a phosphatidylserine (PS)-coated, polymeric (Ac-
Dex), drug-loaded NP designed to enhance uptake into macrophages. The novelty of 
this formulation lies in the inherent ability of PS to enhance the uptake of the NP into 
macrophages, while the Ac-Dex core promotes burst release of the cargo directly in 
the macrophages owing to its acid sensitivity. Curcumin (CUR), a natural product 
isolated from Curcuma longa, was chosen as the model small molecule due to its 
fluorescent properties, low water solubility, and potential clinical applications (43, 45, 
203, 177, 181, 183, 185, 199–202).  
 
3.5 Materials and Methods 
3.5.1 Materials 
Unless stated otherwise, materials were purchased from Sigma Aldrich (St. 
Louis, MO). 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-
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sn-glycero-3-phospho(1’-rac’glycerol) (DPPG), and 1,2-dipalmitoyl-sn-glycero-3-
phospho-L-serine (sodium salt, DPPS) were purchased from Avanti Lipids (Alabaster, 
AL).  
 
3.5.2 Synthesis and Characterization of Acetalated Dextran 
Acetalated dextran (Ac-Dex) was synthesized using a previously described 
method (45, 53). 1 g of lyophilized dextran (9,000-11,000 MW) was dissolved in 10 
mL of anhydrous DMSO with 25 mg of p-toluenesulfonate (PPTS) under nitrogen gas. 
The reaction was carried out for 5 minutes using 5 mL of 2-methoxypropene (2-MOP) 
and was quenched with 1 mL of triethylamine (TEA). The polymer was then 
precipitated in basic water (pH 9), filtered, lyophilized, and stored at -20C. The 
cyclic-to-acyclic (CAC) ratio of Ac-Dex and acetal coverage were verified using 1H 
NMR (Bruker 300 MHz, NMR, MA) as described previously (45, 53, 54).   
 
3.5.3 Synthesis of PVA-Coated Nanoparticles  
PVA-coated, CUR-loaded Ac-Dex NP (PVA-CUR NP) were synthesized 
using a single emulsion/solvent evaporation method (53). 50 mg of Ac-Dex and 1 mg 
of CUR were dissolved in 1 mL of DCM. This organic solution was added to 6 mL of 
3% PVA (in 1x PBS) and the resulting mixture was emulsified using a probe sonicator 
attached to an ultrasonic processer at 120 W and 20 kHz (Q500, Qsonica, Newtown, 
CT) for 1 minute with 1 second on/off pulses. The emulsion was added to 40 mL of 
0.3% PVA and was spun for 4 hours to allow for organic solvent evaporation and 
particle hardening (45). The spinning solution was centrifuged at 3124 x g for 60 
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minutes and particles were redispersed in a 0.1% PVA solution and frozen overnight, 
followed by lyophilization. PVA-coated NP without CUR (PVA-Blank NP) were 
formulated similarly to PVA-CUR NP by omitting CUR from the organic solutions. 
NP samples were stored at -20C.   
 
3.5.4 Synthesis of DPPS and DPPC-Coated Ac-Dex NP 
PVA-coated NP were coated with DPPS via a film hydration method often 
used to make liposomal delivery systems (180, 182, 183, 196, 204, 205). DPPS was 
dissolved in 4 mL of chloroform and methanol (9:1 v/v) (185). The solution was 
subjected to rotary evaporation using a Heidolph 2 rotary evaporator (Schwabach, 
Germany) to create a thin film in a 25 mL round-bottom flask. The film was dried 
under vacuum for 1 hour to remove excess solvent, during which the NP were washed 
with deionized (DI) water to remove excess PVA. The dried film containing the NP 
was then rehydrated with 4 mL of DI water and this solution was sonicated for 30 
minutes, followed by freezing and lyophilization. After lyophilization, the resulting 
NP were stored at -20C. The ratio of lipid to NP during the process was 1:5 (w/w). 
NP coated with DPPC and a small amount of DPPG NP were synthesized using the 
same method with a 5:1 (w/w) DPPC:DPPG ratio and these NP are referred to as 
DPPC-NP.  
 
3.5.5 Nanoparticle Size and Surface Charge Characterization  
Hydrodynamic diameter and surface charge of the NP were evaluated via 
dynamic light scattering (DLS) and zeta potential analysis, respectively, using a 
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Malvern Nano Zetasizer (Malvern Instruments, Worcestershire, UK). The NP were 
diluted to 0.25 mg/mL in DI water and were analyzed at 25C and an angle of 90.  
 
3.5.6 Evaluation of CUR NP Encapsulation Efficiency and Drug Loading  
To determine the amount of CUR encapsulated in the NP systems, NP were 
dissolved in DMSO (1 mg/mL) and the fluorescence of the solutions was analyzed 
using a SpectraMax M2 Plate Reader (Molecular Devices, Sunnyville, CA) at an 
excitation of 420 nm and emission of 520 nm. The encapsulation efficiency (EE) and 
drug loading were calculated using the following equations: 
 
 
 
 
 
3.5.7 Electron Microscopy Imaging Analysis of Nanoparticles 
Images of the NP were taken using a Zeiss Sigma VP Field Emission-Scanning 
Electron Microscope (FE-SEM) (Germany) for analysis of NP morphology. After NP 
were suspended in basic water (15 mg/mL), 1-2 drops of this suspension were added 
to aluminum SEM stubs (TedPella Inc., Redding, CA), and the samples were air dried. 
Dried samples were then coated with a film of gold/palladium alloy using an Emscope 
SC400 sputter coating system at a 20 µA for 75 seconds under argon. Images of the 
NP systems were also captured via a JEOL JEM-2100F transmission electron 
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microscope (TEM, Peabody, MA) for observation of the NP core and outer layers. 1 
µL of 15 mg/mL NP suspension in water were placed on 200 square mesh copper 
grids (Election Microscopy Sciences, Hatfield, PA) and air dried prior to imaging.  
 
3.5.8 Differential Scanning Calorimetry (DSC) Analysis of Nanoparticles 
Thermal phase transitions of the NP systems were analyzed using differential 
scanning calorimetry (DSC) via a TA Q10 DSC system (TA Instruments, New Castle, 
DE) connected to an RSC-90 cooling accessory. For dry-state DSC, samples were 
lyophilized 24 hours prior to analysis. 1-3 mg of NP were analyzed at 10C/min from 
0 to 300C. For wet state analysis, NP were dispersed in DI water (0.1 mM DPPS) and 
15 µL of the NP suspension was added to aluminum pans to be analyzed at 2C/min 
and from 5 to 65C. DSC analysis of the raw materials was also performed.  
 
3.5.9 PVA Coating Quantification 
Quantification of the amount of PVA on the surface of NP was completed 
using a previously described method (206). NP samples were dispersed in DI water (1 
mg/mL). 400 µL of sample solution, 300 µL of iodine solution (1.25 % iodine and 
2.5% potassium iodide), and 1.5 mL of 4% boric acid solution were mixed together for 
20 minutes at room temperature and 100 rpm. Absorbance of the samples was 
measured at a wavelength of 630 nm.  
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3.5.10 Phospholipid Content Quantification 
 Phospholipid quantification was carried out using Stewart’s method (207). 
Briefly, 2.7 g ferric chloride hexahydrate and 3 g ammonium thiocyanate were 
dissolved in 100 mL of distilled water. NP samples were dissolved in chloroform (1 
mg/mL) and were mixed with the ammonium ferrothiocyanate solution via vortexing 
for 5 minutes at a 2:1 (v/v) ratio. After mixing, the solution was allowed to separate, 
and the phospholipid content in the chloroform portion was measured via UV-vis 
spectroscopy at 488 nm (DPPC/G) and 452 nm (DPPS).  
 
3.5.11 In Vitro Drug Release from CUR NP 
Release of CUR from the NP was carried out using a previously established 
centrifugation technique (45). 1 mg/mL NP samples were dispersed in PBS (pH 7.4) 
or sodium acetate buffer (pH 5.35) supplemented using 0.2% Tween® 80 to enhance 
CUR solubility. The suspensions were incubated at 37C and 100 rpm and at 
predetermined time points the suspensions were removed and centrifuged at 23,102 x 
g for 15 minutes. 200 µL of the supernatant was collected and frozen at -20C and 200 
µL of fresh medium was added to the particle solution prior to re-dispersion and re-
incubation. Release samples were mixed with DMSO (1:1 by volume) prior to 
fluorescence spectroscopy analysis at an excitation of 420 nm and emission of 520 nm 
(45). 
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3.5.12 Cell Culture 
Murine macrophage cells (RAW 264.7) and A549 human adenocarcinoma 
cells obtained from American Type Culture Collection (ATCC, Manassas, VA) were 
used for cell culture studies. The cells were maintained at 37°C and 5% CO2 in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal 
bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, Fungizone® (0.5 µg 
amphotericin B, 0.41 µg/mL sodium deoxycholate), and 1 mM sodium pyruvate.  
 
3.5.13 In Vitro Cytotoxicity Analysis of NP 
The cytotoxic effect of the formulated NP on RAW 264.7 macrophages was 
determined using a resazurin assay. Cells were seeded in 96-well plate at 5,000 
cells/well and incubated overnight at 37 °C and were then exposed to varying 
concentrations of PVA-CUR and DPPS-CUR NP (0.001 to 0.2 mg/ml). Untreated 
cells were used as negative controls. After 48 hours, resazurin solution (60 μM) was 
added to the cells and incubated for 3 hours. The fluorescence intensity of resorufin 
produced by viable cells was detected at 544 nm (excitation) and 590 nm (emission) 
using BioTek Cytation 3 plate reader. The relative viability of each sample was 
calculated by: 
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3.5.14 Nitrite Analysis 
 A Griess assay was performed to determine nitric oxide (NO) production by 
macrophages. Following 48-hour incubation with varying concentrations of NP (CUR-
loaded and blank), 96-well plates containing the samples were centrifuged and 50 μL 
of the resulting supernatant was removed from each well. Griess reagents were added 
per manufacturer’s instructions and the absorbance was measured at 550 nm. LPS 
(500 ng/mL), was used to promote NO production as a control.  
 
3.5.15 In Vitro Cellular Uptake Via Spectroscopy and Confocal Microscopy  
 Cellular uptake of CUR-loaded NP by RAW 264.7 and A549 cells was 
observed using a Cytation 3 image reader (BioTek, Winooski, VT). Cells (7,500 
cells/well) were seeded in a 96-well plate and incubated overnight at 37 °C. Cells were 
then incubated with 0.1 mg/ml of NP solutions and equal concentration of CUR for 1 
and 3 hours. After incubation, the media was removed, and the cells were washed 
three times with 200 mM glycine to remove any unbound NP that were not taken up 
by the cells. For quantification of cellular uptake, the fluorescence of the CUR within 
the cells was analyzed via fluorescence spectroscopy at 420 nm (excitation) and 520 
nm (emission).  
RAW 264.7 and A549 cells were seeded into 35 mm glass-bottom petri dishes 
at a concentration of 500,000 cells per dish and allowed to grow overnight. DPPS-
CUR NP, DPPC-CUR NP, or PVA-CUR NP were suspended and bath sonicated in 
cell culture medium at 0.1 mg/mL and were then incubated with cells for 1 or 3 hours. 
Cells were washed 3x in PBS and incubated in fresh media containing CellMask Deep 
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Red (Invitrogen) at 1 L/mL media for 10 minutes. Cells were then fixed with 4% 
paraformaldehyde for 10 minutes and rinsed 3x with PBS. Fresh PBS was added and 
cells were immediately imaged using a Nikon Eclipse Ti2 inverted confocal 
fluorescent microscope. 
 
3.5.16 Statistical Analysis  
All measurements were performed in at least triplicate. Statistical differences 
for in vitro cellular studies was determined using one-way or two-way ANOVA with 
Tukey’s multiple comparisons test (GraphPad Prism version 7). For cumulative drug 
release, Student’s t-Test was used to determine statistical differences. A p-value of < 
0.05 or lower was considered as statistically significant. Values are presented as mean 
 standard deviation.  
 
3.6 Results   
3.6.1 Characterization of Ac-Dex Polymer and Nanoparticles 
Analysis of the acetal coverage and cyclic-to-acyclic (CAC) ratio of Ac-Dex 
following its synthesis was confirmed via NMR. The acetal coverage of Ac-Dex was 
73%, whereas the CAC ratio was 45%. PVA-coated NP were synthesized using the 
emulsion method to create NP with an Ac-Dex polymer core and PVA coating both 
with and without curcumin loading (PVA-CUR NP and PVA-Blank NP, respectively). 
As seen in Table 3.1, PVA-coated NP were 260-275 nm in diameter, exhibited 
polydispersity index (PDI) values of 0.04, and had nearly neutral surface charges (less 
than -3 mV), as seen from the zeta potential values.  
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After the synthesis of PVA-coated NP, the particles were coated with DPPS 
using a thin film hydration method to form DPPS-coated NP, both with and without 
CUR loading (DPPS-CUR NP and DPPS-Blank NP, respectively). The diameters for 
both the blank and CUR-loaded DPPS NP increased by approximately 75 nm in 
comparison to the PVA-coated NP. The PDI values were low for both DPPS NP 
systems (less than 0.21), however, there was a substantial decrease in zeta potential, 
from -3 mV (PVA-coated NP) to -40 mV (DPPS-coated NP) for both blank and CUR-
loaded NP systems.  
The encapsulation efficiency (EE) and drug loading (by mass) of CUR-loaded 
NP were analyzed to quantify the amount of CUR loaded in the particles. Both PVA- 
and DPPS-coated NP exhibited EE values around 25% whereas the drug loading was 
7.1 and 5.2 g CUR/mg NP for PVA-CUR NP and DPPS-CUR NP, respectively.  
 
Table  3.1. Diameter, polydispersity index (PDI), surface charge via zeta potential, 
curcumin encapsulation efficiency, and drug loading of nanoparticle system (mean ± 
standard deviation, n = 3). 
  
Diameter 
(nm) 
PDI 
Zeta 
Potential 
(mV) 
Encapsulation 
Efficiency (%) 
Drug 
loading 
(µg 
drug/mg 
particle) 
PVA-
Blank NP 
262.6 ± 1.9 
0.04 ± 
0.00 
-2.2 ± 3.5 --- --- 
PVA-
CUR NP 
272.6 ± 10.4 
0.04 ± 
0.01 
-3.0 ± 0.6 25.1 ± 0.1 7.1 ± 1.8 
DPPS-
Blank NP 
335.6 ± 3.8 
0.21 ± 
0.43 
-40.4 ± 3.3 --- --- 
DPPS-
CUR NP 
350.5 ± 16.9 
0.13 ± 
0.65 
-40.6 ± 1.3 24.5 ± 0.1 5.2 ± 0.7 
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3.6.2 Morphological Analysis of NP Via Electron Microscopy  
Scanning electron microscopy (SEM) and transmission electron microscopy 
(TEM) were used to analyze the morphology and structure of PVA- and DPPS-coated 
NP loaded with CUR. SEM micrographs indicated that PVA-CUR NP presented 
spherical, smooth morphology and were homogenous with respect to in size (Figure 
3.1, top). TEM images allowed for the visualization of a thin layer around the Ac-Dex 
polymer core, which likely corresponds to the PVA coating. DPPS-CUR NP were 
fairly monodisperse with spherical, smooth morphology as seen via SEM imaging 
(Figure 3.1, bottom). TEM micrographs show a coating on the Ac-Dex NP core, 
likely indicating the DPPS coating on the NP.  
 
 
Figure 3.1. Representative SEM (left) and TEM (middle, right) micrographs of PVA- 
and DPPS-coated, CUR-loaded nanoparticles (PVA-CUR NP and PVA-DPPS NP, 
respectively).  
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3.6.3 Coating Quantification 
The amount of PVA and total phospholipids present in the NP formulations 
were quantified and are presented in Figure 3.2. There was significantly less PVA 
present on the DPPS and DPPC-NP in comparison to the PVA-NP (p < 0.001 and p < 
0.0001, respectively). In addition, significantly more phospholipid was present in 
DPPS and DPPC-NP in comparison to PVA-NP (p < 0.01).  
 
 
Figure 3.2. Quantification of the amount of poly(vinyl alcohol) (PVA) and total 
phospholipid in PVA-CUR, DPPC-CUR, and DPPS-CUR nanoparticles (NP) (* p < 
0.05, **p < 0.01,***p < 0.001 in comparison to PVA-CUR NP). 
 
3.6.4 Differential Scanning Calorimetry (DSC) Thermal Analysis 
Figure 3.3 shows the thermograms of the prepared NP and their corresponding 
raw components in their dry states. An endothermic peak at 90C was present, 
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indicating a bilayer phase transition for the DPPS-coated NP, which is slightly lower 
than the endothermic phase transition temperature of raw DPPS at 99C. An 
endothermic peak was present at 187C for raw PVA, whereas a broadened 
endothermic peak was present at 195C for PVA-coated NP. Both raw CUR and Ac-
Dex exhibited endothermic peaks at 177C, signifying their melting points (45, 53, 
54). These prominent endothermic peaks were not present in the formulated NP. The 
shift from 177C to a broad peak at 195C for PVA-coated NP could be due to the 
interaction between Ac-Dex and PVA. DPPS-coated NP exhibited a broad 
endothermic peak at 165C, potentially due to the removal of the PVA and the 
interaction between the Ac-Dex and DPPS. For wet-state DSC analysis of the 
formulated NP, there were no measurable peaks present for the temperature range 
used; curvature corresponded to the evaporation of water. 
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Figure 3.3.  Differential scanning calorimetry (DSC) thermograms of (A) formulated 
nanoparticles and (B) the raw components that make up the nanoparticle systems in 
their dry state, and (C) formulated nanoparticles in their wet state. 
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3.6.5 In Vitro Drug Release from NP 
The release of CUR from the particles was analyzed at two pH values, 
including pH 7.4 to simulate normal physiological pH and pH 5.35 to approximate the 
pH in macrophages (43). Results in Figure 3.4 shows that there was no significant 
difference in the cumulative release of CUR from PVA-coated versus DPPS-coated 
NP at pH 7.4 after 24 hours (5.2% vs 6.3%), signifying that the NP coating played no 
appreciable role in affecting CUR release at this pH. However, significantly more 
CUR was released at pH 5.35 for both DPPS- and PVA-coated particles (67.8% and 
88.8% release at pH 5.35, respectively) in comparison to pH 7.4 (p < 0.001), 
demonstrating the sensitivity of Ac-Dex to acidic conditions. Furthermore, when 
comparing DPPS- and PVA-coated NP at pH 5.35, significantly more CUR was 
released from NP with a PVA coating, indicating the potential influence of the DPPS 
layer in delaying the release of the cargo (p < 0.05).  
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Figure 3.4. Cumulative release of curcumin (CUR) from nanoparticle systems at pH 7 
and pH 5 (*p < 0.05, **p < 0.01, ***p < 0.001, ns = non-significant). 
 
3.6.6 In Vitro Cytotoxicity Assay 
The impact of the described NP systems on macrophage toxicity was evaluated 
and the results are presented in Figure 3.5. These results indicate that the cells 
exhibited relative viabilities similar to the control (media only) after 48 hours of 
exposure to the NP systems. Increasing the concentration of NP imparted no 
significant change in the viability of cells for PVA-Blank NP, DPPS-Blank NP, or 
PVA-CUR NP for the concentrations tested. However, for DPPS-CUR NP there was a 
slight but statistically significant decrease in the viability of cells at 0.2 mg/ml in 
comparison to the control (p < 0.05).  
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Figure 3.5. Cytotoxicity analysis (relative viability) of nanoparticle systems on RAW 
264.7 macrophages after 48 hours of exposure compared to control (*p < 0.05). 
 
3.6.7 Nitrite Analysis 
 Following 48-hour incubation of NP samples on cells, CUR-loaded and blank 
(control) NP groups produced significantly lower NO in comparison to LPS (p < 
0.0001) (Figure 3.6). The NP groups were the same as the control group (media only) 
statistically, indicating little to no production of NO (208).  
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Figure 3.6. Nitric oxide (NO) production from RAW 264.7 macrophages incubated 
for 48 hours with varying concentrations of nanoparticle formulations or LPS. No 
statistical significance was observed between the groups and control group (no 
treatment) and all were statistically lower than the LPS sample (p < 0.0001). 
 
3.6.8 In Vitro Cellular Uptake  
The cellular uptake of CUR-loaded NP was evaluated in RAW 264.7 
macrophages and A549 adenocarcinoma cells for up to 3 hours as shown in Figure 
3.7. Exploiting the fluorescent properties of CUR, the presence of CUR-loaded NP 
within cells can easily be detected via fluorescence imaging and spectroscopy. After 1 
hour of exposure, significantly more DPPS-coated NP were uptaken by macrophages 
and A549 cells in comparison to PVA-coated NP, DPPC-coated NP, and raw CUR (p 
< 0.0001). For both cell types and all formulations, uptake was not statistically 
different between 1 and 3-hour exposures. In addition, significantly more NP were 
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uptaken in RAW macrophages in comparison to A549 cells for all NP formulations. 
Confocal microscopy confirmed fluorescence spectroscopy quantification, showing 
higher fluorescence in macrophages in comparison to A549 cells, indicating increased 
NP uptake. In addition, more NP were uptaken in DPPS-coated NP in comparison to 
DPPC- and PVA-coated systems in RAW and A549 cells. Images indicate that CUR-
loaded NP were primarily uptaken into the cytoplasm of macrophages, especially for 
DPPS-CUR NP. On the other hand, there were minimal NP located in the cytoplasm 
of A549 cells; instead the NP were more readily located in the cellular membranes. 
 
 
 
Figure 3.7. (Left) Fluorescence spectroscopy analysis of nanoparticle uptake into cells 
and (Right) representative confocal images of nanoparticle uptake by RAW 264.7 
macrophages and A549 cells (scale bar = 10 μm). 
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3.7 Discussion 
3.7.1 Nanoparticle Design and Analysis 
The use of Ac-Dex as a biodegradable NP core for drug delivery can allow for 
a system with tunable and/or triggered degradation (19). For the described NP 
systems, the acetal coverage of Ac-Dex was similar to previous studies (45, 53, 54), 
whereas the CAC ratio was slightly lower. The resulting Ac-Dex was favorable for the 
given application as the adequate acetal coverage imparts hydrophobicity to Ac-Dex, 
allowing for NP formulation and the lower CAC ratio will allow for faster drug release 
at acidic pH (45, 49, 53, 54).  
The increase in diameter and PDI from PVA-coated NP to DPPS-coated NP is 
likely due to the presence of the DPPS coating around the Ac-Dex core. It has been 
shown that an increase in NP diameter can lead to an increase in the uptake of NP into 
macrophages, where particles 200 nm in diameter or greater are often subjected to a 
greater amount of macrophage uptake (57, 84, 209). For this study, larger NP were 
desired and successfully formed (up to 350 nm for DPPS-coated NP), which was 
advantageous since increased macrophage uptake was an objective (43). While DPPS-
coated NP exhibited higher PDI values then PVA-coated NP, these values were still 
low, indicating that all of the formulated NP systems were homogenous with respect 
to size.  
The surface charge of the NP, as indicated by zeta potential, decreased 
significantly (from -3 to -40 mV) upon coating with DPPS. The negative surface 
charge on the DPPS-loaded NP is indicative of the polar head of DPPS being exposed 
to the outer environment, similar to how apoptotic cells present DPPS to the outer 
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leaflet of cells prior to engulfment by macrophages (182, 197). The highly negatively 
surface charge is significantly lower than the -25 mV threshold of being functionally 
negative, indicating that the NP are less likely to aggregate due to electrostatic 
repulsion (79, 80). It should be noted that DPPC-coated NP were also lower than the -
25 mV threshold, indicating a functionally negative charge. In addition, there were no 
differences in size, PDI value, or zeta potential upon the loading of CUR on the NP 
core, indicating that the loading of the model drug had no significant effect on the 
particle systems with respect to these characteristics. 
CUR was encapsulated in the NP for two purposes: 1) to provide a model 
small molecule that is easy to encapsulate owing to its hydrophobicity and 2) the 
inherent fluorescence of CUR within the NP allows for easy fluorescence imaging and 
detection. The encapsulation efficiency (EE) of CUR in the NP was lower than 
previously reported values, which have ranged from 50-88% (183, 185, 203). 
However, since CUR was used as a model small molecule, the EE values were 
satisfactory for this study. Upon coating the NP with DPPS, CUR loading decreased 
slightly but the encapsulation efficiency stayed the same, indicating that the DPPS 
coating did not significantly affect CUR loading. 
The SEM and TEM micrographs indicate that the particles are spherical in 
shape and monodisperse, which correlates to the PDI values for the systems. The 
DPPS-CUR NP seem to have slightly more coating on the NP surfaces, which could 
be due to the increased presence of DPPS.  
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3.7.2 Coating Quantification 
DPPS was selected to coat the nanoparticles owing to its ability to stimulate an 
“eat-me” signal on apoptotic cells (10, 82, 174, 175, 180). For cell studies, DPPC-NP 
were produced as a control lipid system. Initially, the NP systems were coated with 
PVA because it is one of the most widely used polymers in the pharmaceutical 
industry (206) and has been extensively used as a NP coating agent due to the steric 
effects PVA coating imparts on NP, inhibiting aggregation. During the synthesis of 
phospholipid-coated NP, a significant portion of the PVA was washed away prior to 
phospholipid coating, since there is significantly less PVA present on phospholipid-
coated NP in comparison to PVA NP (Figure 3.2). It is also likely that the 
phospholipid coating shielded the remaining PVA upon adsorption to the NP surface, 
as indicated by the low mass presence of PVA on phospholipid-coated NP the high 
mass presence of total phospholipid on the NP, and the changes in surface charge 
(Figure 3.2).   
 
3.7.3 Thermal Analysis of Nanoparticle Formulations 
 Dry-state DSC thermograms indicated the presence of DPPS in the DPPS-
coated NP via the bilayer phase transition peak that occurred at 90C for the NP, 
which is slightly lower than the raw DPPS endothermic peak present at 99C. This 
transition signifies the presence of bilayer formation of the phospholipid around the 
Ac-Dex polymer core in its dry state. The decrease in the transition temperature is 
likely due to the interaction of the multiple components in the formulation. As the 
transition temperatures of the NP formulations were just below or well above 100C, 
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they are likely to be stable in the dry state and can be easily reconstituted before use 
(145). The endothermic peak that raw CUR exhibited at 177C was not observed in 
CUR-loaded NP. According to our previous research (data not shown), this is likely 
due a limitation in DSC detection with relation to the actual amount of CUR in the 
samples.  
In studies using liposomal formulations, DSC is used to assess the transition 
temperature(s) in the systems in order to determine the presence and state of bilayers 
and the differences associated between blank liposomes and modified/drug-loaded 
systems (204, 205). For wet-state analysis (Figure 3.3C), there was no endothermic 
peak present around 50-60C, which is the temperature at which the gel/crystalline 
phase transition occurs for PS bilayers in aqueous solutions (193, 210). Such a 
phenomenon could have occurred based on the preparation method used, as described 
previously. In certain cases, self-assembly of polymer-lipid structures can occur via 
hydrophobic interaction between the lipid tails and a polymeric core simultaneously 
with hydrophilic interactions between the polar head and external environment (211). 
Due to the concentration dependency of DSC, it is more likely that the DPPS 
concentration may have been too low to be detectable by thermal analysis, like that of 
the CUR detection limit mentioned previously. It should be noted that the curvature of 
the thermograms in Figure 3.3C corresponds to the evaporation of water, which is not 
shown in the thermogram. Overall, the results indicate the presence of DPPS on the 
surface of the NP, further strengthening what has been previously described with 
respect to successful DPPS coating of the described systems. 
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3.7.4 Curcumin Release from Nanoparticles 
The release from CUR from PVA- and DPPS-coated NP was evaluated to 
demonstrate the ability of the system to provide sustained release of a therapeutic 
agent and to show the acid-sensitive nature of Ac-Dex. Ac-Dex is known to degrade 
more quickly in acidic environments (19). In a previous study, Ac-Dex particles 
released 60% of their camptothecin payload after 7 days (49) and 15% of rapamycin 
after 10 days (43) at pH of 7.4. Comparatively, at pH values of 5 or lower, Ac-Dex 
particles released 100% of their content in as little as 24 hours (36, 43, 45). For this 
study, at pH 5.35, 9.3% of CUR was initially released from DPPS-CUR NP and 
29.2% was released after 1 hour, followed by a sustained release of cargo of 67.8% 
after 24 hours, when equilibrium is reached. At pH 7.4, both NP systems exhibited 
minimal CUR release, demonstrating the stability of Ac-Dex in neutral pH. However, 
both systems exhibited triggered release at pH 5.35, exhibiting a significantly higher 
total release in comparison to their pH 7.4 counterparts (p < 0.001). Overall, these data 
indicate a more stable NP formulation at pH 7.4 and the potential for triggered release 
at pH 5.35, corresponding to stability in circulation and burst release in macrophages, 
respectively.  
 
3.7.5 Cytotoxic Analysis and Macrophage Uptake of Nanoparticles 
 To assess the in vitro cytotoxicity of the NP formulations on RAW 264.7 
macrophages, the cells were exposed to the systems for 48 hours. It was observed that 
the NP systems were not toxic to the cells, however, a slight, but significant, decrease 
in viability of RAW 264.7 cells for DPPS-CUR NP at 0.2 mg/ml was observed 
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(Figure 3.5). This decrease in viability was minimal and could easily be overcome by 
using lower concentrations of the particles in future studies. Overall, these results 
indicate the safety of the described NP for a time period longer than necessary for NP 
uptake into macrophages, indicating that they are safe to use in the intended fashion. 
  Nanomaterials may provoke immune and inflammation responses following 
interactions with multiple biological entities (57). To assess inflammatory and immune 
response stimulation, NO production was measured using a Griess assay, where LPS 
was used as a positive control to stimulate NO production in RAW macrophages. It 
was observed that NP at varying concentrations stimulated significantly less NO 
production in comparison to LPS and resulted in NO concentrations comparable to 
that of the control (media only). Results indicated that blank NP caused NO 
production at concentrations similar to that of the CUR-loaded NP. These data indicate 
both blank and CUR-loaded formulations produced minimal NO and that CUR did not 
play an active role in the inhibition of NO production.  
Since the purpose of this study was to formulate acid-sensitive NP capable of 
enhanced macrophage uptake, the ability of DPPS-coated NP to be uptaken by 
macrophages was evaluated, with A549 cells acting as control tissue. PVA and DPPC-
coated NP were used as other coatings for comparison to DPPS. Several 
environmental and physicochemical factors are known to influence the cellular uptake 
of NP into macrophages. The preferential uptake of DPPS-CUR NP by macrophages 
in comparison to PVA-CUR NP and DPPC-CUR NP is likely due to the DPPS coating 
on the Ac-Dex polymeric core. Confocal microscopy in tandem with fluorescence 
quantification of CUR-loaded NP within the cells confirm the uptake of DPPS-CUR-
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NP and localization to the cytoplasm of macrophages. The presence of DPPS on the 
cellular surface is known to cause an “eat-me” signal in cells that are transitioning 
toward an apoptotic state, causing macrophages to identify and phagocytose the dying 
cells (82, 173–175, 183). Therefore, in terms of recognition, the DPPS coating on the 
Ac-Dex NP was identified by the macrophages, which produced the necessary 
phagocytotic action, resulting in cellular uptake of the particles (10, 82, 182, 183, 194, 
196). In most cases, apoptosis is initiated by the presence DPPS and other signaling 
pathways such as receptor-ligand interactions or identification of PS binding proteins 
produced by phagocytes. However, there is a debate as to whether DPPS recognition 
by itself is sufficient for the uptake of apoptotic cells by phagocytotic cells (174, 194). 
In the case of nanoparticles, is has been shown that a DPPS coating alone is sufficient 
for uptake, as seen in this current study and otherwise (10, 180, 183).  
Another consideration for cellular uptake of the described particles is in terms 
of their physicochemical characteristics. Stimulation of phagocytosis of nanoparticle-
based delivery systems via macrophages is also dependent on the size and shape of the 
particles. Since the DPPS-CUR NP were greater than 300 nm in diameter, it is likely 
that these NP were phagocytosed not only because of the DPPS layer, but also because 
of their size (43, 84, 212). It is well known that surface charge can play a role in 
biological interactions. Interestingly, surface charge did not play a role in the uptake of 
the NP, as shown by the similar charges of DPPC and DPPS-coated NP that produced 
significantly different uptake quantities (79, 80, 84). This phenomenon could also 
explain the minimal phagocytosis of the PVA-coated NP and confirm the effect of 
DPPS on the uptake of the NP. Overall, the results indicate the successful uptake of 
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DPPS-coated NP into macrophages, indicating that these systems could be used for the 
treatment of a multitude of diseases involving infected cells.  
 
3.8 Conclusions 
Macrophages can harbor infectious agents that lead to potentially fatal diseases 
such as TB and HIV. Due to this, treatment of these diseases is challenging and 
therefore, the goal of this study was to design a delivery system that would enhance 
the uptake of nanoparticles into macrophages, allowing for targeted delivery, a 
decrease of systemic side effects, and decreased treatment times. Results showed that 
both PVA-coated and DPPS-coated NP were monodisperse and that there was a 
significant increase in size upon DPPS coating. The surface charge of the DPPS NP 
was -40 mV, indicating that DPPS was present on the surface of the NP. This was 
further confirmed via PVA quantification, which indicated minimal amounts of PVA 
on the DPPS NP. DSC results confirmed the presence of a DPPS bilayer on the NP 
surface and the likely stability of the NP during synthesis and storage conditions. 
CUR-loaded NP successfully encapsulated CUR and this agent was more quickly 
released in acidic conditions in comparison to neutral pH owing to the acid sensitivity 
of Ac-Dex. In addition, CUR-loaded NP exhibited sustained release of CUR. PVA-
coated NP were not readily phagocytosed by macrophages, whereas DPPS-coated NP 
were phagocytosed within 1 hour of exposure, showing the physiological relevance of 
the DPPS coating for the enhanced delivery to macrophages. These data show that the 
particles can potentially deliver therapeutic agents throughout the body with fewer 
concerns of systemic drug exposure, and when exposed to macrophages, the particles 
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are capable of being phagocytosed relatively quickly. Therefore, the combination of 
Ac-Dex and DPPS can be a viable option for targeted delivery for macrophage-
associated diseases. 
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4.1 Abstract  
Objective: The objective of this study was to design and characterize aerosol 
microparticles capable of providing sustained release of the model water-soluble 
compound sulforhodamine B (SRB) in addition to achieving aerosol dispersion.  
Significance: Modulating the release of water-soluble compounds remains an ongoing 
challenge in pulmonary drug delivery  
Methods: SRB was mixed with water to form an aqueous solution, while acetalated 
dextran (Ac-Dex) was mixed with isopropyl alcohol to form an organic solution. 
These two solutions were mixed together, resulting in the precipitation of SRB, and 
the solution was spray dried to produce dry powder microparticles (MP). MP were 
characterized for their morphology, size, release kinetics at different pH, aerosol 
dispersion, and cellular interactions.  
Results: Ac-Dex MP exhibited corrugated morphology with diameters around 1 m 
and experimental mass median aerodynamic diameters from 2.06 to 2.86 m. With 
respect to aerosol dispersion, the MP deposited in all stages of a Next Generation 
Impactor, with > 90% fine particle fraction. MP exhibited encapsulation efficiencies > 
129% with SRB loading values up to 16.7 g SRB/mg MP. Release kinetics 
demonstrated sustained release of SRB at pH 7 and faster release at pH 5. In vitro 
experiments showed minimal cytotoxicity, successful uptake of MP in epithelial cells, 
and no disruption to the integrity of epithelial monolayers up MP exposure.  
Conclusions: Overall, the Ac-Dex MP systems demonstrated the ability to provide 
sustained the release of a water-soluble therapeutics in addition to aerosol delivery of 
the particles to the lungs.   
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4.2 Keywords: Aerosol; sustained released; pulmonary drug delivery; microparticles; 
water-soluble compounds; Acetalated dextran  
 
4.3 Abbreviations: 2-methoxypropene (2-MOP), acetalated dextran (Ac-Dex), cyclic-
to-acyclic ration (CAC),  dichloromethane (DCM), dimethyl sulfoxide (DMSO), 
deionized (DI) water, differential scanning calorimetry (DSC), dynamic light 
scattering (DLS), encapsulation efficiency (EE), Karl Fischer Titration (KFT), 
Microparticles (MP), Net Generation Impactor (NGI), phosphate buffered saline 
(PBS), poly(vinyl alcohol) (PVA), poly(lactic-co-glycolic acid) (PLGA), p-
toluenesulfonate (PPTS), polarized light microscopy (PLM), scanning electron 
microscopy (SEM), sulforhodamine B (SRB), triethylamine (TEA) 
 
4.4 Introduction 
Lung diseases remain a persistent health concern and as a result, it is necessary 
to continue to develop new drug delivery systems to improve the treatments in this 
area (145, 213). Dry powder aerosol formulations are an important option in the 
treatment of pulmonary diseases since they promote localized delivery, avoidance of 
first-pass metabolism, concentrated drug dosing, and a rapid onset of action, thereby 
reducing systemic toxicity and dosing frequency (135, 214).  
 Two challenges in formulating dry powder therapeutics are the diversity in 
delivered compounds, especially with respect to their solubility and/or crystallinity 
(145), and the need for formulations capable of sustained release (130). Highly water-
soluble agents including antibiotics (153), anti-cancer small molecules (215, 216), 
proteins (48, 217, 218), and gene-related therapeutics (209, 213, 219) have been 
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formulated as dry powders. However, owing to their solubility and the nature of 
particle formulation methods, water-soluble therapeutics can be challenging to 
formulate. In addition, their high solubility in aqueous solutions results in fast 
dissolution (220) and this can result in unfavorable pharmacokinetic and 
pharmacodynamic outcomes (2, 130, 220, 221). Also, water soluble therapeutics are 
usually administered orally or parenterally routinely to maintain favorable 
pharmacokinetics. Frequent systemic administration of these therapeutics can result in 
toxicity (130). Therefore, it is desirable to develop formulations capable of localizing 
and controlling the release of water-soluble therapeutics to decrease systemic 
administration (and side effects) as well as increasing the control over the release of 
encapsulated cargo., especially for pulmonary drug delivery applications.   
To modulate the release of therapeutics, it is common practice to use polymer 
carriers such as poly(lactic-co-glycolic acid) (PLGA) (2). Unfortunately, PLGA-based 
formulations often exhibit significant burst release of its cargo and the degradation of 
PLGA can result in undesirable changes in the microenvironment. An alternative 
option is acetalated dextran (Ac-Dex), a synthetic derivative of the FDA-approved 
excipient dextran (19). Using a one-step reaction, hydroxyl groups on dextran are 
acetalated, thereby modifying the polymer to be hydrophobic (19, 40, 222). The 
reaction time of Ac-Dex can be easily controlled, resulting in tunability of the ratio of 
cyclic-to-acyclic acetal groups  (35, 40, 50, 222), which can be  used to control the 
degradation rates of Ac-Dex drug delivery systems. The degradation of Ac-Dex occurs 
within a few hours in an acidic environments and as long as weeks in a neutral 
environment, making it ideal for sustained release of therapeutics, depending on the 
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application (45). In addition, the degradation by-products of Ac-Dex have been shown 
to be non-toxic and does not produce immunogenic and inflammatory responses (19), 
which is especially important for pulmonary applications.  
Ac-Dex has been used in a wide variety of drug delivery applications, 
including the delivery of anticancer agents (49, 50), antibiotic and antiviral agents (41, 
47, 51), and immunosuppressive small molecules (43). In addition, our previous 
studies have demonstrated the successful design of several Ac-Dex formulations for 
sustained release of therapeutics in the lungs (53, 54, 223). Despite this work, there is 
no comprehensive study on the design and characterization of Ac-Dex-based systems 
that can allow for sustained release of water-soluble therapeutics within the lungs. The 
goal of the present study is the development and characterization of novel Ac-Dex 
microparticle (MP) systems. We hypothesize that the resulting Ac-Dex MP can allow 
for successful encapsulation and sustained of a model water-soluble compound, while 
allowing for effective aerosol dispersion of the particles for pulmonary applications.  
The novelty of the formulations lies in the use of Ac-Dex for formulate aerosol 
MP to encapsulate a water-soluble compound, the formulation method itself (aqueous 
in organic precipitation), and the successful encapsulation and release of a water-
soluble compound, sulforhodamine B (SRB). SRB was chosen as a model compound 
owing to its high solubility in water (> 100 mg/ml) and fluorescent properties. The 
ensuing formulation could be utilized for a wide variety of water-soluble compounds, 
demonstrating the significance of the described study and results. 
 
4.5 Materials and Methods 
4.5.1 Materials 
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Detailed information on the materials can be found in Supplemental 
Information. 
 
4.5.2 Synthesis and characterization of acetalated dextran 
Ac-Dex was synthesized using  previously described methods with minor 
modifications (45). 1 g of lyophilized dextran and 25-30 mg of PPTS were dissolved 
in 10 mL of DMSO under nitrogen gas. The reaction was carried out for 5 minutes or 
3 hours by adding 5 mL or 6.5 mL of 2-MOP, respectively. The reaction was 
quenched with 1 mL of TEA. The polymer was precipitated in basic water (pH 9), 
vacuum filtered, frozen overnight, and lyophilized. Corresponding to their degradation 
rates, products of 5-minute and 3-hour reaction times are designated as Fast-Ac-Dex 
and Slow-Ac-Dex, respectively. The cyclic-to-acyclic (CAC) ratio of Ac-Dex and 
acetal coverage were verified using 1H NMR (Bruker 300 MHz, NMR, MA) as 
previously described (45).  
 
4.5.3 Microparticle synthesis via spray drying 
 MP systems were prepared via spray drying using a Büchi B-290 spray dryer 
(Büchi Labortechnik, AG, Switzerland) in closed mode (organic solution; Ac-Dex MP 
systems) or open mode (aqueous solution; mannitol system) as seen in Figure 4.1. It 
should be noted that pure SRB was not spray dried in this study. Instead, SRB 
encapsulated in mannitol was used as the control due to their combined water 
solubility. For Ac-Dex MP, 1 mL of 4 mg/mL SRB solution in deionized (DI) water 
was slowly injected into a spinning solution of 400 mg Ac-Dex in 20 mL of 
isopropanol to create a water-organic (W/O) solution prior to spray drying, resulting in 
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an initial loading of 1% w/w SRB. For mannitol MP, 1 ml of 4 mg/mL SRB was 
added to a 20 mg/mL solution containing approximately 400 mg of mannitol (1% w/w 
SRB). SRB-excipient solutions were spray dried using optimized conditions (Table 
4.1) based on a previous study (44). While the type of excipient, set inlet temperature, 
and pump rate were varied, the following conditions were kept constant: 0.7 mm 
nozzle diameter, aspiration rate of 40 m3/h, nozzle cleaner rate of 0, and gas flow rate 
of 414 L/h using ultra high pure nitrogen.  
 
 
Figure 4.1. Schematic of microparticle preparation including mixing of aqueous 
solution containing sulforhodamine (SRB) and water and organic solution containing 
acetalated dextran (Ac-Dex) and isopropyl alcohol (IPA) to form a water/organic 
(W/O) solution prior to spray drying and microparticle formation. 
 
 
Table 4.1. Spray drying parameters for particle sets, including the reaction time used 
for acetalated dextran (Ac-Dex) synthesis, spray drying parameters (set inlet 
temperature and pump rate), and actual inlet and outlet temperatures during the spray 
drying process. The particle naming convention is as follows: ‘Fast’ refers to 5-minute 
Ac-Dex (fast degrading), ‘Slow’ refers to 3-hour Ac-Dex (slow degrading), the 
temperature value is the set inlet temperature setting, and ‘LowP’, ‘MedP’, and 
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‘HighP’ refers to 10, 30, and 100% pump rates, respectively (mean ± standard 
deviation, n = 3). 
System Ac-Dex 
Reaction 
Time 
Set Inlet 
Temperature 
(C) 
Pump 
Rate 
(%) 
Actual Inlet 
Temperature 
(C) 
Actual Outlet 
Temperature 
(C) 
Fast-100C-
MedP 
5-minute 100 30 100.8 ± 1.9 57.8 ± 2.2 
Fast-150C-
MedP 
5-minute 150 30 150.1 ± 0.8 77.8 ± 6.7 
Fast-100C-
HighP 
5-minute 100 100 102.6 ± 2.9 57.1 ± 6.6 
Slow-100C-
MedP 
3-hour 100 30 103.6 ± 2.5 56.2 ± 2.2 
Slow-150C-
MedP 
3-hour 150 30 153.8 ± 2.3 83.1 ±3.6 
Slow-100C-
HighP 
3-hour 100 100 104.2 ± 2.0 59.2 ± 3.5 
Man-100C-
LowP 
--- 100 10 101.4 ± 1.7 55.2  ± 1.6 
 
 
 
4.5.4 Morphology, size, and tapped density analysis 
Images of MP systems were obtained using a Zeiss Sigma VP Field Emission-
Scanning Electron Microscope (FE-SEM, Germany) following a previously described 
preparation method, and were taken at 10,000x and 5kV  (54). To determine the 
geometric diameter (dg) of the MP, particles in SEM micrographs were analyzed using 
ImageJ software (Systat, San Jose, CA, USA) using at least 100 MP of each system. 
The hydrodynamic diameter of MP systems was analyzed using a Malvern Nano 
Zetasizer (Malvern Instruments, Worcestershire, UK). Ac-Dex MP were diluted to 
0.25 mg/mL in DI water and were analyzed at 25C and 90. Mannitol MP samples 
were analyzed in the same manner using chloroform. The tapped density of particles 
was measured using a previously described method (45). The density of the MP 
systems was calculated via the following equation:  
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r =
m
V       
     
where  is the tapped density, m is the mass, and V is the volume occupied by MP. 
The theoretical mass median aerodynamic diameter (MMADT) of the MP systems 
were then calculated via:  
 
    	
MMAD
T
= d
g
r
r
ref    
       
where dg is the geometric diameter,  is the tapped density, and ρref is the reference 
density of solid polymer (1 g/cm3).  
 
4.5.5 In vitro aerosol performance  
 In vitro aerosol performance of MP systems were evaluated using a Next 
Generation Impactor (NGI, MSP Corporation, Shoreview, MN) as previously 
described  (54). For Q = 60 L/min, cutoffs for each stage of the NGI are 8.06 µm 
(stage 1), 4.46 µm (stage 2), 2.82 µm (stage 3), 1.66 µm (stage 4), 0.94 µm (stage 5), 
0.55 µm (stage 6) and 0.34 µm (stage 7). Fine particle fraction (FPF), respirable 
fraction (RF), and emitted dose (ED) were calculated using the following equations: 
 
Fine	Particle	Fraction	(FPF)	=	
Mass	of	MP	on	stages	2	through	7
Total	MP	mass	on	all	stages
	x	100%
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Respirable	Fraction	(RF)	=	
Mass	of	MP	on	stages	2	through	7
Initial	MP	mass	loaded	into	capsules
	x	100%
 
 
	
Emitted	Dose	(ED)	=	
Initial	MP	mass	in	capsules	-	Final	MP	mass	in	capsules
Initial	MP	mass	in	capsules	
	x	100%
 
    
The experimental mass median aerodynamic diameter (MMADE) and geometric 
standard deviation (GSD) for the MP systems were determined using a Mathematica® 
program written by Dr. Warren Finlay (224). 
 
 
4.5.6 Crystallinity and phase transition analysis  
Thermal phase transitions of MP systems and raw materials were analyzed via 
differential scanning calorimetry (DSC) using a TA Q10 DSC system (TA 
Instruments, New Castle, DE) connected to an RSC-90 cooling accessory. 3-5 mg of 
sample were hermetically sealed in aluminum pans and were placed into the DSC 
furnace. Samples were heated from 0-200°C at a rate of 10°/min (45). The crystallinity 
of MP systems and raw materials were examined by X-ray diffraction (XRD) using a 
Rigaku Multiflex X-ray diffractometer (The Woodlands, TX) as described previously 
with a scan range of 5-60° in 2Θ with a width of 0.1 and scan rate of 1°/min. (45). 
Images of MP systems and raw materials were observed for birefringence via 
polarized light microscopy (PLM) using an AmScope polarized microscope (Irvine, 
CA) (225). Samples were mounted onto microscope slides, smeared with mineral oil 
for dispersion, and imaged at 10x magnification at room temperature.  
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4.5.7 Analysis of water content via Karl Fischer titration  
 Water content of the MP systems was quantified via Karl Fischer (KF) titration 
using a 737 KF coulometer (Metrohm, Riverview, FL, USA). 3 mg of powder was 
dissolved in methanol and the resulting solution was injected into the KF cell filled 
with Hydranal® and the amount of water was analyzed. Pure solvent was also injected 
as a background sample. 
 
 
4.5.8 Encapsulation efficiency and drug loading analysis  
To determine the amount of SRB encapsulated in the MP systems, MP were 
dissolved in methanol or deionized water (1 mg/mL) and quantified via fluorescence 
spectroscopy using a Cytation 3 plate reader (BioTek, Winooski, VT, USA) at  
565/586 nm (ex/em) (226). The encapsulation efficiency (EE) and drug loading (DL) 
of MP were calculated using the following equations: 
 
        	
EE=
Actualmassof SRBinMP
Theoreticalmassof SRBinMP
x100%
  
    
     	
DL	=	
Massof SRBinMP
Mass inMP       
 
4.5.9 Drug release and release kinetic analysis  
Release of SRB from MP was carried out using a centrifugation technique. 10 
mg/mL samples were created by dispersing MP in phosphate buffered solution (PBS, 
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pH 7.4) or sodium acetate buffer (pH 5.35). The suspensions were incubated at 37C 
and 100 rpm and centrifuged at 23,102 x g for 5 minutes at predetermined time points. 
400 µL of the supernatant was collected and frozen at -20C and 400 µL of fresh 
buffer was added to the particle solution prior to re-dispersion. Supernatant samples 
were supplemented with equal parts methanol or water to solubilize any remaining 
excipient. Analysis was carried out via fluorescence spectroscopy and normalized 
SRB release was calculated as follows:  
 
Normalized	SRB	Release	=	
Mass	Released	at	t	=	time
Total	Mass	Released
x100%
 
 
Drug release kinetics of SRB released from the MP were evaluated using six 
different models, including: zero-order, first-order, Higuchi, Korsmeyer-Peppas (a.k.a. 
the power law), Peppas-Sahlin, and Corrigan. The model parameters and coefficient of 
determination (R2) for each model were determined using least squares regression. For 
zero-order, first-order, Higuchi, and Korsmeyer-Peppas models, the equations were 
linearized, and the slope, intercept, and R2 values were determined using the ‘linest’ 
function in Microsoft Excel prior to calculation of the model parameters. For Peppas-
Sahlin and Corrigan, the model parameters and R2 values were determined using the 
‘fminsearch’ function in MATLAB. A detailed description of the release models and 
parameters can be found in Supplemental Information.  
 
4.5.10 Cell Culture 
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A549, H441, and Calu-3 cells were obtained from ATCC (Manassas, Va, 
USA). A549 cells were maintained at 37°C and 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum, 100 U/ml 
penicillin, 100 μg/ml streptomycin, Fungizone® (0.5 µg amphotericin B, 0.41 µg/mL 
sodium deoxycholate), and 1 mM sodium pyruvate. H441 and Calu-3 cells were 
maintained in RPMI and MEM media, respectively, with the same additives as 
DMEM.  
 
4.5.11 Cellular uptake 
To observe inherent cellular uptake of MP systems, A549, H441, and Calu-3 
cells were incubated with MP and observed using a Cytation 3 image reader (BioTek, 
Winooski, VT, USA). Cells (5,000 cells/well) were seeded in a 24-well plate and 
incubated overnight at 37 °C. Cells were incubated with MP containing 10 μM SRB 
for 3 hours. After incubation, media was removed, and the cells were washed twice 
with 1x PBS to remove any unbound MP. To visualize cellular uptake, images were 
captured using fluorescence imaging. For quantification of cellular uptake, the 
presence of the SRB within the cells was analyzed via fluorescence spectroscopy at 
565/586 nm (ex/em). 
 
4.5.12 In vitro cytotoxicity assay  
The cytotoxic effect of the formulated MP on A549 cells was determined. 
Cells were seeded in 96-well plate at 5,000 cells/well and incubated overnight. The 
following day, cells were exposed to varying concentrations of SRB (0.01 to 10 μM) 
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from formulated MP and cytotoxicity was assessed. 60 μM resazurin was added to the 
cells and incubated for 3 hours. The fluorescence intensity of resorufin produced by 
viable cells was detected at 544 nm (excitation) and 590 nm (emission). The relative 
viability of each sample was calculated by: 
 
Relative	Viability	=	
Sample	Fluorescence	Intensity
Control	Fluorescence	Intensity
x100%
 
 
4.5.13 In vitro transepithelial electrical resistance of lung epithelial cells exposed to 
MP 
H441 cells were used for transepithelial electrical resistant (TEER) analysis 
following microparticle exposure. Cells were seeded at 1 x 105 cells/ml in well plates 
with 12 mm Transwells® having 0.4 µm pore size (Corning Incorporated, Corning, 
NY, USA) with 1.5 mL of media on the basolateral side and 0.5 mL of media on the 
apical side. On day 3, the cells were transitioned to air-interface conditions (AIC) with 
0.5 mL of media on the basolateral side and no media on the apical side. Prior to 
TEER measurements, 0.5 ml of media was added to the apical side of the Transwell 
and the resistance was measured using an EVOM voltohmmeter with an STX2 
electrode (World Precision Instruments, INC., Sarasota, FL, USA). Once the 
resistance stabilized to 100 Ω cm2, indicating a confluent monolayer, the cells were 
exposed to 1 mg of the microparticles. Resistance measurements were taken for five 
days after exposure and the TEER of cells exposed to particles was compared to the 
control cells to calculate the percent TEER response as follows: 
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TEER%Control=
Sampleresistance
Control resistance
x100%
               
 
4.5.14 Statistical analysis 
All measurements were performed in at least triplicate. Statistical significance 
for in vitro cellular studies was determined using two-way ANOVA with Tukey's 
multiple comparisons test (GraphPad Prism version 7). A p-value of < 0.05 was 
considered as statistically significant. Values were presented as mean  standard 
deviation unless stated otherwise.  
 
4.6 Results 
4.6.1 Confirmation of acetalated dextran (Ac-Dex) synthesis and microparticle 
morphology 
Fast-Ac-Dex exhibited a cyclic acetal coverage (CAC) ratio of 43.5% and -OH 
conversion of 75.1%, while Slow-Ac-Dex exhibited an 80.6% CAC ratio and 93.8% -
OH conversion. As seen in Figure 4.2, Ac-Dex MP systems exhibited corrugated 
(raisin-like) morphology, whereas mannitol MP exhibited spherical morphology.  
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Figure 4.2. Representative scanning electron microscopy micrographs of spray-dried 
sulforhodamine B (SRB)-loaded microparticles. Images were taken at 10,000x. Scale 
bar = 2µm. 
 
4.6.2 Size analysis and in vitro aerosol performance 
Microparticles were analyzed for their size and density to aid in the 
understanding of particle performance (Table 4.2). Hydrodynamic diameters for Ac-
Dex MP ranged from 0.96 to 1.63 m whereas PDI values ranged from 0.16 to 0.30. 
Tapped density values ranged from 0.117 to 0.157 g/cm3 and the resulting theoretical 
MMAD values were between 0.20 and 0.41 m. MP systems deposited on all stages 
of the impactor (Figure 4.3), with the largest amounts depositing on stages 2 through 
5. Experimental MMAD values for the MP ranged from 2.1 to 2.9 m, while the 
geometric standard deviations ranged from 1.9 to 2.7 m. In comparison mannitol MP 
exhibited similar hydrodynamic diameter, density, and GSD and higher PDI, 
MMADT, and MMADEXP than Ac-Dex MP. Fine particle fraction (FPF), respirable 
fraction (RF), and emitted dose (ED) values are reported in Figures 4.3 and B1, 
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representing the aerosol performance properties of the inhaled dry powders. FPF were 
> 90%, RF ranged from 65 to 78%, and ED were > 88%.  
 
Table 4.2. Characteristics of microparticle systems, including (Top) hydrodynamic 
diameter and polydispersity index (PDI) via dynamic light scattering, tapped density, 
theoretical mass median aerodynamic diameter (MMADT) via tapped density 
calculations, and experimental mass median aerodynamic diameter (MMADEXP) and 
geometric standard deviation (GSD) via Next Generation Impactor analysis and 
(Bottom) water content, encapsulation efficiency, and drug loading of sulforhodamine 
B (SRB) in the microparticles (mean ± standard deviation, n = 3). 
System Hydrodynamic 
Diameter (µm) 
PDI Tapped 
Density 
(g/cm3) 
MMADT 
(µm) 
MMADE
XP (µm) 
Geometr
ic 
diamete
r (dg) 
(µm) 
GSD  
Fast-
100C-
MedP 
1.01 ± 0.27 0.24 ± 
0.03 
0.139 ± 
0.002 
0.39 ± 
0.19 
2.60 ± 
0.30 
1.13  ± 
0.56 
2.66 ± 
1.53 
Fast-
150C-
MedP 
0.98 ± 0.03 0.29 ± 
0.03 
0.157 ± 
0.016 
0.20 ± 
0.07 
2.06 ± 
0.25  
0.53  ± 
0.19 
1.86 ± 
0.13 
Fast-
100C-
HighP 
1.57 ± 0.06 0.60 ± 
0.19 
0.130 ± 
0.004 
0.41 ± 
0.17 
2.78 ± 
0.30 
1.11  ± 
0.45 
2.05 ± 
0.17 
Slow-
100C-
MedP 
1.18 ± 0.03 0.22 ± 
0.01 
0.135 ± 
0.003 
0.41 ± 
0.18 
2.29 ± 
0.29 
1.15  ± 
0.51 
1.93 ± 
0.06 
Slow-
150C-
MedP 
0.96 ± 0.03 0.16 ± 
0.03 
0.117 ± 
0.003 
0.40 ± 
0.20 
2.61± 
0.45 
1.01  ± 
0.51 
2.00 ± 
0.26  
Slow-
100C-
HighP 
1.63 ± 0.08 0.39 ± 
0.37 
0.131 ± 
0.006 
0.20 ± 
0.09 
2.86 ± 
0.23 
0.556  ± 
0.24 
1.96 ± 
0.22 
Man-
100C-
LowP 
1.48 ± 0.10 0.74 ± 
0.02  
0.129 ± 
0.003 
1.05 ± 
0.67 
3.73 ± 
0.80 
3.53  ± 
2.3 
1.92 ± 
0.21 
        
System Water Content 
(%) 
SRB Encapsulation 
Efficiency (%) 
Drug Loading  
(µg SRB/mg particles) 
Fast-100C-MedP 2.2 ± 0.7 153 ± 45 15.2 ± 4.5 
 84 
 
Fast-150C-MedP 3.2 ± 0.7 165 ± 53 16.1 ± 4.8 
Fast-100C-HighP 1.9 ± 0.2 148 ± 27 15.7 ± 4.5 
Slow-100C-MedP  3.2 ± 0.7 147 ± 29 14.7 ± 2.9 
Slow-150C-MedP 2.9 ± 1.5 142 ± 36 14.0 ± 3.5 
Slow-100C-HighP 3.5 ± 1.1 129 ± 29 16.7 ± 2.9 
Man-100C-LowP  2.8 ± 1.4 118 ± 27 11.6 ± 2.7 
 
 
 
Figure 4.3. (Top) Aerosol dispersion analysis of fast and slow degrading particles in 
stages 1-7 of a Next Generation Impactor, expressed as percent particle deposition per 
stage (mean ± standard deviation, n = 3). For Q = 60 L/min, cutoffs for each stage of 
the NGI are: 8.06 µm (stage 1), 4.46 µm (stage 2), 2.82 µm (stage 3), 1.66 µm (stage 
4), 0.94 µm (stage 5), 0.55 µm (stage 6) and 0.34 µm (stage 7). (Bottom) 
Aerosolization performance properties of spray-dried particle systems, including fine 
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particle fraction (FPF), respirable fraction (RF), and emitted dose (ED) (mean ± 
standard deviation, n = 3). 
 
4.6.3 Solid state analysis 
 MP systems exhibited water content values  3.5% (Table 4.2) and DSC 
thermograms (Figure 4.2A) indicate that the formulations exhibited thermal 
transitions above 90C (shown by arrows), which is greater than the spray dryer outlet 
temperatures (Table 4.1, e.g. temperatures that the particles were exposed to during 
spray drying). XRD diffractograms (Figure 4.2B) indicate the transition of SRB from 
a crystalline to amorphous state when spray-dried and encapsulated in Ac-Dex, and a 
crystalline state following encapsulation in mannitol, which is similar to previous 
reports (53, 54). Also, characteristic peaks of SRB were present in the mannitol 
formulation (Figure 4.2B, as indicated by arrows). Absence of diffraction in Fast-Ac-
Dex suggest minimal to no crystallinity of the material (44). For confirmation, PLM 
images were taken of the raw materials and MP systems (Figure 4.2C). Raw 
mannitol, raw SRB, and a mixture of the two are visibly crystalline, as indicated by 
the high level of birefringency. Images show minimal birefringency for Fast-150C-
MedP and Slow-100C-HighP, whereas other systems appear to have none. 
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Figure 4.4. (A) Representative differential scanning calorimetry thermograms of raw 
materials used during the spray drying of particles and of sulforhodamine B (SRB)-
loaded microparticles. (B) Representative x-ray diffractograms of raw materials used 
during the spray drying of particles and of sulforhodamine B (SRB)-loaded 
microparticles. (C) Polarized light microscopy images of microparticle systems and 
raw materials. Crystals in microparticle systems are indicated by arrows, if applicable. 
Scale bar = 0.1 mm. 
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4.6.4 Drug loading, in vitro drug release, and release kinetic analysis  
All particles exhibited SRB encapsulation efficiency (EE) values greater than 
100% (Table 4.2), whereas SRB drug loading (DL) ranged from 11.6 to 16.1 µg of 
SRB to mg of MP. The exceptionally high EE is mainly based on the loss of polymer 
during synthesis; smaller particles are captured by the filter rather than the collection 
vial and cyclone. This polymer loss results in an inherent increase in EE. Although 
drug loading values were exceptionally low, for the purposes of the study, they were 
determined to be acceptable.  
  The in vitro drug release of SRB from all MP systems in phosphate buffer (pH 
7.4) and sodium acetate buffer (pH 5.35) at physiological temperature was performed 
to simulate release in circulation and acidic states of the body, respectively (Figure 
4.5). Results show that both types of Ac-Dex MP systems released 100% of SRB 
between 4 and 6 hours in acidic pH, which is characteristic of the acid-sensitive nature 
of Ac-Dex (19, 36). Although all Fast-Ac-Dex MP systems except for Fast-100C-
MedP reach equilibrium at 36 hours, at physiological pH, Fast-Ac-Dex MP released 
100% of SRB at 96 hours. In comparison, Slow-Ac-Dex MP released 100% of SRB at 
108 hours. Mannitol MP released 100% of SRB in 4 hours at both pH values (while 
reaching equilibrium in the first 2 hours), corresponding to its high solubility in 
aqueous environments and lack of pH sensitivity. 
To investigate the theoretical outcome of the release of SRB from the designed 
systems and their subsequent release mechanism(s), the release profiles were fitted to 
several models, including zero-order, first-order, Higuchi, Korsmeyer-Peppas, Peppas-
Sahlin, and Corrigan. Table 4.3 shows the results of the best-fit models at each pH, 
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their associated constants, and their R2 values (all of which were  0.90). At pH 5.35, 
Ac-Dex MP exhibited both Corrigan and Peppas-Sahlin-type release kinetics. The 
fraction of drug release (FB,in) show that the majority of the drug cargo was released 
and the KC values varied from system-to-system (227). Drug release kinetics at pH 7.4 
for Fast-Ac-Dex and mannitol MP were best fit to the Korsmeyer-Peppas model, 
which relates the amount of drug released to the time elapsed (228). The n variable in 
the model determines the type of diffusion from the formulation. Results show that 
particle systems exhibiting Korsmeyer-Peppas release kinetics have n < 0.43, 
indicating that the release from the MP followed Fickian diffusion (229). Slow-Ac-
Dex MP exhibited first-order release kinetics at pH 7.4 and the values of K1 for Slow-
Ac-Dex systems are considerably smaller in relation to the values of t and the 
constant, n. The values from this study show that Slow-Ac-Dex systems exhibited 
short burst release followed by sustained release (2). 
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Figure 4.5. Normalized percent weight release profiles of sulforhodamine-B (SRB) 
microparticles at pH 5 and pH 7 as a function of time (mean ± standard deviation, n = 
3). The insert for pH 7, fast degrading particles represents the zoomed in release for 
mannitol microparticles. 
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Table 4.3 Best-fit drug release kinetics model for each microparticle system, the 
corresponding fitted parameters, and corresponding coefficient of determination (R2) 
values. KKP is the Korsmeyer release rate constant, n is the drug release exponent, K1 
is the first-order release rate constant, KC is the first-order rate constant associated 
with kinetics of the burst release for Corrigan, FB,in is the fraction of drug release 
during burst. The units for the constants are as follows: KKP [=] h
-n, K1 [=] h
-1, n [=] 
unitless, KC [=] h
-1, FB,in [=] unitless (fraction), k1 [=] h
-m, k2 [=] h
-2m, m [=] unitless. 
 
pH = 5.35 
System Model Constants R2 
Fast-100°C-MedP Corrigan KC = 0.673 FB,in = 0.979 0.964 
Fast-150°C-MedP Corrigan KC = 1.211 FB,in = 0.989 0.997 
Fast-100°C-HighP Corrigan KC = 1.306 FB,in = 0.992 0.993 
Slow-100°C-MedP Corrigan KC = 0.632  FB,in = 1.030 0.985 
Slow-150°C-MedP Corrigan KC = 0.481 FB,in = 1.014 0.990 
Slow-100°C-HighP Corrigan KC = 1.358 FB,in = 1.010 0.995 
Man-100°C-LowP n/a --- ---   --- 
pH = 5.35 
System Model Constants           R2 
Fast-100°C-MedP Peppas-Sahlin k1 = 0.6304 k2 = 0.1524 m = 0.0912 0.969 
Fast-150°C-MedP Peppas-Sahlin k1 = 0.6926 k2 = 0.1130  m = 0.0763 0.969 
Fast-100°C-HighP Peppas-Sahlin k1 = 0.6930 k2 = 0.1298 m = 0.0699 0.979 
Slow-100°C-MedP Peppas-Sahlin k1 = 0.6132 k2 = 0.1922 m = 0.0643 0.970 
Slow-150°C-MedP Peppas-Sahlin k1 = 0.4767  k2 = 0.2894  m = 0.0581 0.978 
Slow-100°C-HighP Peppas-Sahlin k1 = 0.6912 k2 = 0.2520 m = 0.0237 0.967 
Man-100C-LowP Peppas-Sahlin --- --- --- --- 
pH = 7.4 
System Model Constants        R2 
Fast-100°C-MedP Korsmeyer-Peppas KKP = 0.314 n = 0.218 0.907 
Fast-150°C-MedP Korsmeyer-Peppas KKP = 0.546 n = 0.117 0.921 
Fast-100°C-HighP Korsmeyer-Peppas KKP = 0.498 n = 0.152 0.987 
Slow-100°C-MedP First Order K1 = 0.0248 --- 0.942 
Slow-150°C-MedP First Order K1 = 0.0267 --- 0.970 
Slow-100°C-HighP First Order K1 = 0.0272 --- 0.904 
Man-100°C-LowP Korsmeyer-Peppas KKP = 0.831 n = 0.103 0.927 
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4.6.5 Cytotoxicity, uptake, and transepithelial electrical resistance of cells  
The integrity of H441 air-interface culture (AIC) lung epithelial cells exposed 
to aerosolized MP was analyzed using transepithelial electrical resistance (TEER). The 
presence of an initial confluent monolayer was confirmed by steady TEER values (> 
100 Ω cm2) following 9-11 days of culturing in AIC conditions. Beginning 24 hours 
after exposure to the formulated particles, TEER was evaluated. As seen in Figure 
4.6A, the TEER values remained statistically the same or higher following MP 
exposure (p > 0.05) and were similar to that of the control. The influence of the 
formulated MP systems on A549 viability was evaluated (Figure 4.6B) and results 
indicate that the cells exposed to MP exhibited viability values similar to those the 
control for up to 108 hours of exposure. Increasing the concentration of microparticles 
imparted no significant change in the viability of A549 cells for the concentrations 
tested. The cellular uptake of the MP systems was evaluated in A549, Calu-3, and 
H441 cells for 3 hours (Figure 4.6C). The presence of SRB-loaded MP within the 
cells were detected via fluorescence imaging and spectroscopy. Significantly more 
Fast-Ac-Dex MP were uptaken by all the cells in comparison to Slow-Ac-Dex MP. In 
addition, more MP uptake was evident in Calu-3 and H441 cells in comparison to 
A549 cells. The morphology of the cells was similar at all time points and following 
exposure to the MP.  
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Figure 4.6. Results from experiments where cells were exposed to sulforhodamine B 
(SRB)-loaded microparticles (MP), including (A) Transepithelial electrical resistance 
(TEER) data for H441 cells exposed to microparticle systems from day -9 to day 5, 
where day 0 was the particle exposure day. The particle naming convention 
corresponds to the following: F100M = Fast-100C-MedP, S100M = Slow-100C-
MedP, F150M = Fast-150C-MedP, S150M = Slow-150C-MedP, F100H = Fast-
100C-HighP, and S100H = Slow-100C-HighP; (B) Viability of A549 cells exposed 
to SRB MP (* p < 0.05, **p < 0.01, mean ± standard deviation, n = 3); and (C) SRB 
MP uptake by A549, Calu-3, and H441 cell lines (* p < 0.05, **p < 0.01, ***p < 
0.001, mean ± standard deviation, n = 3). 
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4.7 Discussion 
Ac-Dex is a biodegradable polymer that exhibits tunable degradation rates 
based on the synthesis time and formation and type of acetals (cyclic versus acyclic). 
A higher CAC ratio results in slower degradation, whereas higher -OH conversion 
results in Ac-Dex that is more hydrophobic, allowing for facile particle formation. For 
the described formulations, Fast-Ac-Dex data were similar to previously reported data 
(19, 40, 43, 45, 54) and Slow-Ac-Dex values were similar or higher than previous 
reports  (45, 49). Furthermore, the increase in CAC for Slow-Ac-Dex correlates to 
slower release, as shown in the kinetic release analysis. 
Differences in the morphology of the MP systems (Ac-Dex MP = corrugated, 
mannitol MP = spherical) are due to the difference in surface tensions and boiling 
points of the solvents used during spray drying. For Ac-Dex MP, solvent droplets 
comprised primarily of IPA (and Ac-Dex) and a small amount water (and SRB) are 
vaporized rapidly due to the high inlet temperatures (≥ 100 C) in relation to the 
boiling point of IPA (82.6 C). Owing to the low surface tension of IPA and fast 
solvent vaporization during spray drying, the droplets dry quickly and a thin polymer 
wall forms, leading to hollow particles. As the particles cool, the walls of the droplets 
collapse, resulting in a corrugated structure (45, 145). In contrast, the spray-dried 
mannitol solution contains only mannitol and SRB in water. Due to the high surface 
tension and boiling point of water, these droplets are able to hold their spherical shape 
more efficiently during the drying process, allowing for the formation of spherical 
particles (145).  
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The analysis of particle hydrodynamic diameters in solution allow for the 
observation of MP in their wet state, and PDI values indicate that the particles were 
fairly homogenous in size in this state. The tapped densities of the MP systems were 
much lower than the reference density (1 g/cm3). For Ac-Dex MP, low density values 
are likely due to the corrugated morphology of the particles and the void space of both 
particle types in their dry state can lower the overall density values. The low tapped 
density values resulted in theoretical MMAD values that are smaller than the 
geometric diameters, indicating that the actual densities of the MP are higher than 
reported here.  
Experimental MMAD and GSD values were similar to previously reported 
data (45). Theoretical MMAD of all particle sets were less than MMADEXP, which is 
likely due to the agglomeration of the dry particles during aerosolization (45). 
MMADECP values were within the 1 – 5 m range required for aerosol deposition of 
particles into the lungs (135). FPF values > 90% indicate that the aerosolized particles 
have the potential to deposit in the lower airways. High ED values indicate that the 
majority of particles are released from the capsules. In addition, a significant portion 
of particles have the potential to be delivered from the inhaler to the lower airways of 
the lungs, as indicated by high RF values. In all cases, these values were higher in 
comparison to previously published reports (45, 218, 230–232). Particles that were 
synthesized using a high pump rate exhibited higher PDI, hydrodynamic diameters, 
and experimental MMAD values. This is likely due to the lower exposure time to 
heated gas due to the higher pump rate. Solutions dried using these settings allow for 
more rapid drying in comparison to other settings, which allows for uneven formation 
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of particles. Particles synthesized using a temperature of 100°C had higher geometric 
diameters and hydrodynamic diameters compared to systems synthesized with 150°C 
(44). 
Solid-state analysis of the MP indicate that the systems exhibit water content 
values low enough to be ideal for dry powder storage and stability (145). Higher water 
content is associated with destabilization of amorphous formulations, causing re-
crystallization of the cargo (145, 213, 233), which can be detrimental to the 
formulation and overall therapeutic outcomes. Furthermore, high water content can 
cause hydrolysis of Ac-Dex and particle cohesion, which would result in larger 
particle size and a shift in particle deposition toward the upper regions of the lungs 
(44). DSC data indicate that the transition temperatures of the compounds are 50C  
greater than their storage conditions, which can allow for product stability (145). 
Comparison of DSC and PLM data confirm minimal to no crystallinity in the Ac-Dex 
formulations compared to high crystallinity in mannitol formulations.  
The drug release patterns of Ac-Dex MP at acidic and physiological pH values 
are similar to previous studies  (35, 45, 49). By controlling the reaction time of Ac-
Dex, alterations in the acetalation of dextran altered the release kinetics. However, 
regardless of Ac-Dex synthesis time, hydrolysis of acetal groups accelerated in acidic 
conditions, resulting in fast drug release from the NP. The  Corrigan model was 
developed to evaluate initial burst release that occurs in drug delivery systems (234). 
When exposed to acidic pH conditions, Ac-Dex degrades quickly, which allows for 
burst release, resulting in a release pattern similar to those described in a previous 
report which studied 152 drug release experiments to evaluate burst release (227, 234, 
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235). The variation in KC values is likely related to differences in the diffusion 
coefficient and solubility of the drug, as well as the differences in surface area of the 
systems (235). Since all of the systems encapsulated the same compound and were 
similar in diameter, the effect of surface area is the likely caused by the different 
morphologies of the particles (145).  
The Peppas-Sahlin kinetics model (236) is based on a two-kinetic constant 
theory, with k1 relating to the Fickian contribution (diffusion) and k2 relating to the 
case II relaxation contribution (erosion). Using k1 and k2, the R/F ratio was calculated 
to determine the dominating contribution occurring during drug release (Table SII) 
(237). For R/F > 1, the case II relaxational contribution dominates, indicating erosion 
of the delivery system, whereas diffusion is the dominating contribution for R/F < 1. 
Based on constants k1 and k2, and R/F values, drug release from all particle systems at 
pH 5.35 are predicted to be based on  diffusion (k1 < k2 and R/F < 1, in all cases) (236, 
237). This is likely due to the highly water soluble nature of SRB (2, 236).  
As stated previously, at pH 5.35 all particle systems exhibited Peppas-Sahlin or 
Corrigan type kinetics. Peppas-Sahlin showed that release kinetics were based on the 
diffusion of SRB from the systems rather than erosion of the systems. Corrigan 
showed that all systems exhibited burst release kinetics, in which all of the 
encapsulated SRB was released and the kinetics was based on the surface area of the 
system. Overall, the systems exposed to pH 5.35 exhibited a combination of burst 
release and exceptionally quick diffusion, likely due to not only the acidic sensitivity 
of Ac-Dex, but also the high solubility of SRB. At pH 7.4, Fast-Ac-Dex particles 
exhibited Korsmeyer-Peppas release kinetics, whereas Slow-Ac-Dex exhibited first-
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order release kinetics. Fast-Ac-Dex systems experienced diffusion-based release, 
likely due to the high solubility of SRB and the extremely slow of erosion of Ac-Dex. 
Slow-Ac-Dex systems demonstrated short burst release, followed by a highly-
controlled rate of release for SRB, likely due to the high stability (more so than Fast-
Ac-Dex) of Slow-Ac-Dex at neutral pH values. Overall, the release kinetics for all 
systems are ideal for various diseases of the lung, where physiological diseases can be 
treated with sustained release formulations and diseases associated with acidic 
conditions (cancer, infectious diseases) can utilize burst release in a controllable 
manner. 
The formulated MP were evaluated using several cell culture techniques as 
described in the Results. The presence of steady TEER values following exposure of 
AIC H441 cells to the MP indicates that the systems do not impact the lung epithelium 
integrity. H441 cells were used for TEER due to their epithelial cell typing. 
Furthermore, the MP were not toxic to A549, a commonly used lung cancer cell line, 
at the concentrations and times tested. Finally, results demonstrated that Slow-Ac-Dex 
MP have the ability to be uptaken into H441, A549, and Calu-3 cells. Uptake is likely 
due to two phenomena. One explanation is the lipophilicity of the polymer; too high of 
lipophilicity (Slow-Ac-Dex) can inhibit the uptake of particles in comparison to those 
that are not as lipophilic. Another explanation could be due to the fact that the cell 
types are cancerous and inherently have leaky channels. Based on the results, it is 
likely that both explanations contributed to the uptake of the MP systems. Overall, the 
results indicate that the MP are likely safe for pulmonary delivery applications. 
 
4.8 Conclusions 
 98 
 
Ac-Dex MP systems were successfully developed results in the sustained 
release of a water-soluble compound. Both ‘Fast’ and ‘Slow’ MP systems were 
corrugated in structure, similar in size, and in physical states. The formulations 
exhibited aerosol dispersion properties that demonstrate they could be used for 
pulmonary drug delivery. Release of SRB from the formulations was dependent on 
both the degradation rate of the polymer and the pH conditions. These factors allowed 
for burst, sustained, and/or controlled release of the cargo depending on the 
environment and type of Ac-Dex. In terms of biological interactions, the MP systems 
showed minimal toxicity and no disruption of epithelial monolayer integrity, while 
Fast-Ac-Dex particles showed significant uptake compared to their Slow-Ac-Dex 
counterparts. Overall, the engineered Ac-Dex MP systems developed have the 
capability of not only delivering water-soluble agents to the whole lung, but also 
controlling the release of such cargo. These results confirm our previously mentioned 
hypothesis. 
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5.1 Abstract 
Tangential flow filtration (TFF) is a commonly used purification method in a 
multitude of fields, including particle engineering. Despite this, there is no 
comprehensive examination on the effects of key parameters of TFF on nanoparticle 
(NP) outcomes (characteristics). Therefore, this study aims to investigate the influence 
of various factors on the characteristics of TFF-purified NP, while using 
centrifugation, the most commonly used NP purification method, as a comparison. In 
total, this study is divided into three parts: (i) a design of experiment approach to 
investigate the influence of transmembrane pressure, flow rate, and initial drug loading 
on NP characteristics using paclitaxel as a model small molecule; (ii) determination of 
the optimized parameters following statistical analysis; and (iii) evaluation in the 
variability of NP characteristics following encapsulation of different small molecules. 
Once the optimized parameters were determined, paclitaxel tacrolimus and 
resveratrol-loaded NP were synthesized and purified via centrifugation and TFF. 
Results indicated that both key parameters and encapsulated drug play significant roles 
in the outcomes of purified NP, and that TFF can serve as a suitable scale-up 
purification method, demonstrating significantly smaller NP diameters and increased 
drug loading in comparison to centrifugation.  
 
5.2 Keywords 
Tangential flow filtration, nanoparticle purification, Box-Behnken design, acetalated 
dextran; drug delivery 
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5.3 1Abbreviations  
(Included as footnote) 
 
5.4 Introduction  
The application of nanotechnology in biomedical and pharmaceutical sciences has 
drastically impacted the way diseases are diagnosed and treated (5, 238, 239). 
Polymeric nanoparticles (NP) are attractive drug delivery systems, owing to their 
biocompatibility, tunable characteristics, and environmental responsiveness (1, 2, 19). 
Commonly used fabrication methods for polymeric NP include single or double 
emulsification, nanoprecipitation, and salting out (240). Following nanoparticle 
fabrication, a purification process is often used to remove additives, surfactants, and/or 
unencapsulated drug.    
The most common method used for NP purification is ultracentrifugation, which 
utilizes centrifugal force to separate final products from undesired material (24). 
Similarly, diafiltrating centrifugal devices can be used to separate NP from their raw 
materials by combining centrifugal forces with the use of filters with a known 
molecular weight cut off (MWCO) that are added to centrifuge tubes (24, 31). While 
these are simple, easy separation processes, the g forces generated during 
centrifugation can lead to challenges during the purification process. The compaction 
of NP by these forces can result in caking and densely packed NP pellets that require 
                                                 
1
2-methoxypropene: 2-MOP; Acetalated dextran: Ac-Dex; Acetonitrile; ACN; Box-Behnken design: 
BBD; Dimethyl sulfoxide: DMSO; drug loading : DL; encapsulation efficiency: EE; nanoparticle: NP; 
poly(vinyl alcohol): PVA; paclitaxel : PTX; pyridinium p-toluenesulfonate: PPTS; phosphate buffered 
saline: PBS; resveratrol: RSV; tacrolimus: TAC; triethylamine: TEA; Trifluoroacetic acid: TFA; 
tangential flow filtration: TFF; transmembrane pressure: TMP; ultra performance liquid 
chromatography: UPLC;  zeta potential: ZP.  
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laborious methods to ensure effective redispersion, which may lead to inconsistencies 
in NP characteristics due to batch-to-batch variation (241, 242). Additionally, 
centrifuges have a finite capacity for containers, hindering the overall feasibility of 
batch manufacturing via centrifugation. 
Tangential flow filtration (TFF) is a commonly-used purification method for 
biomacromolecules (e.g. proteins), food and beverages, and water filtration (23, 243, 
244). Contrary to conventional dead-end filtration methods, filtration by TFF occurs 
when a fluid containing solutes flows tangentially to a filter, allowing for purification 
in a dynamic manner. Solutes of interest can be retained, while waste products can be 
removed. Additionally, a constant concentration gradient is maintained, allowing for 
the removal of excess media and solute re-concentration (23) 
The first study that used TFF processing for NP purification was published in 
1993, where polymeric NP were purified following salting out fabrication (245). Since 
then, numerous studies have utilized TFF systems in NP fabrication processes such as 
purification and coating (31, 34, 246, 247). In fact, TFF has received significant 
attention as a consistent and continuous method of purification for liposomal 
formulations (248). 
Despite this work, there has not been a comprehensive examination of the effects 
of key parameters of TFF on the outcomes of NP characteristics. Although studies and 
reviews have suggested the impacts that TFF processing parameters (transmembrane 
pressure (TMP), flow rate, flux, etc.) have on the characteristics of NP formulations 
(size, charge, dispersity, etc.), there has not been an experimental study to assess these 
suggestions (23, 24, 241, 242). The purpose of this study was to investigate the effects 
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of TFF flow rate and TMP as well as initial drug loading on NP characteristics 
utilizing a design of experiment (DoE) approach. Acetalated dextran (Ac-Dex) was 
chosen as the model polymeric carrier, as it has attracted increasing attention as a drug 
delivery polymer due to its biocompatibility and biodegradability (19). Compared to 
poly(lactic-co-glycolic acid), Ac-Dex has been shown to be easily tunable and pH 
responsive, allowing it to be used for a variety of disease states (44). Moreover, Ac-
Dex can be easily produced through a facile one-step reaction, allowing for cost- and 
time-effective synthesis. Paclitaxel (PTX) was chosen as the model drug in the DoE 
studies. In addition to PTX, two other hydrophobic small molecules i.e. tacrolimus 
(TAC) and resveratrol (RSV) were utilized to understand the effect of purification 
process (centrifugation vs TFF) on the NP characteristics.  
 
5.5 Experimental Methods 
5.5.1 Materials  
Dextran from Leuconostoc mesenteroides (9,000-11,000 MW), pyridinium p-
toluenesulfonate (PPTS, ≥ 99.9%), 2-methoxypropene (2-MOP, ≥ 97%), triethylamine 
(TEA, ≥ 99%), anhydrous dimethyl sulfoxide (DMSO, ≥ 99.9%), dichloromethane 
(DCM, ≥  99.9%) and trifluoroacetic acid (TFA) were purchased from Sigma Aldrich 
(St. Louis, MO, USA). Poly(vinyl alcohol)  (PVA), iodine, boric acid (≥ 99.5%), 
potassium iodide ( ≥ 99%), acetonitrile (HPLC grade), phosphoric acid (85%), and 
phosphate buffered saline (PBS) were purchased from Fisher Scientific (Waltham, 
MA, USA). Tacrolimus (TAC) and paclitaxel (PTX) were purchased from LC 
Laboratories (Woburn, MA). Resveratrol (RSV) was purchased from AdipoGen (San 
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Diego, CA). The physical characteristics of paclitaxel, tacrolimus, and resveratrol can 
be found in Supplemental Information. 
 
5.5.2 Design of experiment study 
5.5.2.1 Nanoparticle synthesis and purification via centrifugation 
Acetalated dextran (Ac-Dex) was synthesized using a previously reported method 
(44) and drug-loaded Ac-Dex NP were synthesized via a single emulsion method. 
Briefly, PTX and Ac-Dex (40 mg total; 2, 6, or 10 wt% initial PTX loading) were 
dissolved in 1 mL DCM to form the organic phase. 6 mL of 3% (w/v) poly(vinyl 
alcohol) (PVA) in phosphate buffer saline (PBS) (aqueous phase) was added to the 
organic phase. The organic-water mixture was sonicated (Q500 Sonicator; Qsonica, 
Newtown, CT) at 70% amplitude for 30 s with 1 s on/off pulses. The resulting 
emulsion was added to 40 mL of 0.3% (w/v) PVA spinning solution and stirred for 4 
hours to allow for particle hardening and solvent evaporation. NP formulations were 
made in triplicate. 
 
5.5.2.2 Nanoparticle purification via tangential flow filtration (TFF) 
NP suspensions were made as described above and prior to purification, several 
batches of NP were combined and added to a TFF system (KRi2 KrosFlo, Spectrum 
Inc., Rancho Dominguez, CA). The NP suspensions underwent diafiltration using a 
500 kDa polyethersulfone-modified (mPES) MidiKros® hollow fiber filter until 15 mL 
of concentrated NP remained. 10 mL of 0.05% (w/v) PVA was added to the 
suspension, which was further concentrated to a final volume of 5 mL. The TFF 
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parameters used are outlined in Table 5.1. The resulting NP were frozen at -20°C, 
lyophilized, and stored at -20°C.  
 
5.5.2.3 Design of experiment using Box-Behnken design 
Box-Behnken design (BBD) was used to examine the impact of the key tangential 
flow filtration (TFF) parameters on the characteristics of nanoparticle (NP) 
formulations via a Design Expert software (Version 11, Stat-Ease, Inc. Minneapolis, 
MN). The factors evaluated were transmembrane pressure (TMP), TFF flow rate, and 
initial PTX loading in the initial NP formulations. The BBD responses were NP 
diameter, polydispersity index (PDI), zeta potential, PVA content, and actual PTX 
loading. To normalize drug content values, PVA content was subtracted from drug 
loading. The results were analyzed using ANOVA. The complete design and 
formulation parameter variables are shown in Table 5.1.  
 
Table 5.1 (Top) Tangential flow filtration factors (transmembrane pressure (TMP), 
flow rate, and initial paclitaxel (PTX) loading) and levels (low, medium, high) for the 
Box-Behnken Design of nanoparticle formulations. (Bottom) Randomized processing 
parameters from Design-Expert used to synthesize the initial batch formulations. 
Factors Low Medium High 
TMP (psi)  2 11 20 
Flow Rate (mL/min) 50 100 150 
Initial PTX Loading (wt %) 2 6 10 
 
Formulation 
TMP  
(psi) 
TFF Flow Rate 
(mL/min) 
PTX Loading  
(weight %) 
1 11 50 10 
2 2 50 6 
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3 11 100 6 
4 20 100 2 
5 11 100 6 
6 20 100 10 
7 2 150 6 
8 20 50 6 
9 2 100 10 
10 11 150 2 
11 2 100 2 
12 11 100 6 
13 11 100 6 
14 11 150 10 
15 11 100 6 
16 11 50 2 
17 20 150 6 
 
5.5.2.4 Nanoparticle characterization  
The hydrodynamic diameters and surface charges of NP were evaluated via 
dynamic light scattering (DLS) and zeta potential analysis, respectively, using a 
Malvern Nano Zetasizer (Malvern Instruments, Worcestershire, UK) as previously 
described (45). In order to determine the actual drug loading in the NP, formulations 
were dissolved in mobile phase and their drug content was evaluated via ultra 
performance liquid chromatography (UPLC, LaChrom, Hitachi, Japan), as described 
in Supplemental Materials. Theoretical and actual drug loading (DL) was calculated 
using the following equations: 
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The amount of PVA in the NP formulations was determined using a previously 
reported method (Procházková et al., 2014). The actual DL of the NP formulations 
without PVA was calculated using the following equation:  
 
 
 
The morphology of the NP formulations was assessed using a Zeiss Sigma VP 
Field Emission-Scanning Electron Microscope (FE-SEM) (Germany). To demonstrate 
the presence of the PVA coating, lyophilized NP were suspended in basic water (pH 9) 
and one to two drops of this suspension were transferred to aluminum SEM stubs 
(TedPella Inc., Redding, CA) prior to air drying. To show particle morphology and 
size in the absence of the PVA coating, NP were washed once with DI water, and 
centrifuged at 23,102 g for 2 minutes to remove PVA prior to sample preparation and 
imaging.  
 
5.5.3 Comparison of the purification processes 
PTX, tacrolimus (TAC), and resveratrol (RSV)-loaded Ac-Dex NP with 10 wt% 
initial drug loading were prepared and purified via either centrifugation or TFF. For 
centrifugation, deionized (DI) water was added to dilute the NP formulations, which 
were centrifuged at 19,802 g for 20 min to concentrate the NP. The NP were then 
washed with DI water and centrifuged at 19,802 g for 20 min again. The resulting NP 
were dispersed in 0.1% (w/v) PVA to prevent particle agglomeration. Purification via 
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TFF was performed as described above, where TMP and flow rate were set at 2 psi 
and 150 mL/min, respectively. The NP were then frozen at -20°C, lyophilized, and 
stored at -20°C for further analysis.   
In order to understand the impact of the purification method on the final drug and 
PVA present in the NP formulations, samples were collected at different stages of the 
purification processes (Figure 5.1) and analyzed. During centrifugation, samples were 
collected after the first DI water wash and initial centrifugation (Supernatant 1) and 
after the secondary DI water wash and centrifugation (Supernatant 2). During TFF, 
samples of the filtrate were collected following the initial diafiltration (Step 1) and 
concentration (Step 2). Immediately following TFF, the membrane was washed with 
70% ethanol to remove any remaining particles and free drug and this solution was 
collected for drug and PVA content analysis (Membrane Cleaning, Step 3).  
 
 
Figure 5.1. Schematic overview of the nanoparticle (NP) purification processes of 
 109 
 
centrifugation and tangential flow filtration (TFF). For centrifugation, deionized (DI) 
water was added to the NP suspension, following by centrifugation (Washing, 
Supernatant 1), this step was repeated (Washing, Supernatant 2), and the NP were 
resuspended in 0.1% poly(vinyl alcohol) (PVA). For TFF, the NP suspension 
underwent an initial filtration (Diafiltration, Step 1), then a concentration step 
occurred following addition of 0.05% PVA to get 15 mL of concentration NP 
(Concentration, Step 2), and finally the TFF membrane was cleaned to collect residual 
residue (Membrane Cleaning, Step 3). 
 
5.5.4 Statistical analysis  
All measurements were performed in at least triplicate and values are given as 
mean ± standard deviation. Statistical significance was determined using ANOVA or 
Student’s t-test, where a p-value of < 0.05 was considered statistically significant. 
Statistical analysis was performed using either Design Expert software or GraphPad 
Prism.   
 
5.6 Results  
 
5.6.1 Design of experiment results for PTX-loaded Ac-Dex NP (PTX-NP) 
Figure 5.2 shows the BBD study responses (NP characteristics) from the initial 
batch formulations including NP diameter, PDI, zeta potential, PVA content, and 
actual PTX loading. NP diameters following TFF purification ranged from 141 to 172 
nm, and the PDI and zeta potential (ZP) values varied slightly from sample-to-sample 
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(0.07 to 0.22 and -4.6 to -1.4 mV, respectively). The PVA content in the NP 
formulations ranged from 0.32 to 0.77 mg PVA/mg NP. Actual PTX loading ranged 
from 0.026 to 0.086 mg PTX/mg NP whereas PTX loading (less PVA) ranged from 
0.052 to 0.23 mg PTX/mg NP.  
Table 5.2 and Figure 5.3 show the overall impact of the BBD factors on the 
experimental responses for PTX-NP purified via TFF. TFF flow rate imparted an 
inverse effect on the average PDI of TFF-purified NP as determined by the negative 
coefficient estimate (CE) value and slope of the graph and high R-squared value. 
Initial PTX loading had a significant impact on NP zeta potential (p < 0.05). On the 
other hand, initial PTX loading had a positive impact on actual PTX loading as 
demonstrated by positive CE and slope as well as high R-squared values. The 
combination of TMP and flow rate had an impact on the overall diameter of the NP 
(Figure 5.3, Bottom), where low TMP and high flow rate (or vice versa) allowed for 
the production of NP with small diameters. The contour maps show how TMP, flow 
rate, and initial PTX loading had a combined effect on the overall diameter.  
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Figure 5.2. Characteristics of paclitaxel-loaded nanoparticles (PTX NP) purified using 
tangential flow filtration (TFF) including diameter and polydispersity index (PDI); 
zeta potential; poly(vinyl alcohol) (PVA) content; paclitaxel (PTX) loading (with and 
without PVA). Mean ± standard deviation, n = 3. 
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Table 5.2. Overview of the influences of tangential flow filtration factors 
(transmembrane pressure (TMP), flow rate, and initial paclitaxel (PTX) loading) on 
nanoparticle properties, including diameter, polydispersity index (PDI), zeta potential, 
poly(vinyl alcohol) (PVA) content, actual PTX loading (DL) with and without PVA, 
and their corresponding coefficient estimates (CE), where applicable. (--- = no 
significance, * = p < 0.05). 
 
Diameter 
(nm) 
PDI 
Zeta 
Potential 
(mV) 
PVA 
Content 
(mg 
PVA/m
g NP) 
Actual 
PTX DL 
(mg 
PTX/mg 
NP) 
 
Actu
al 
PTX 
DL 
(Less 
PVA
) (mg 
PTX/ 
mg 
NP) 
TMP 
(psi) 
 
--- --- --- --- --- --- 
Flow 
Rate 
(mL/mi
n) 
 
--- 
*  
CE: -0.032 
p-value: 
0.023 
--- --- --- --- 
Initial 
PTX 
Loading 
(wt %) 
 
--- --- 
* 
CE: 0.59 
p-value: 
0.02 
--- 
* 
CE: 0.017 
p-value: 
0.02 
--- 
TMP 
and 
Flow 
Rate 
*  
CE: 9.96 
p-value: 
0.014 
--- --- --- --- --- 
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Figure 5.3 Data showing the effect of tangential flow filtration (TFF) process 
parameters on nanoparticle (NP) characteristics. (Top Left) The effect of TFF flow 
rate on nanoparticle polydispersion index (PDI). (Top Center) The effect of Initial 
PTX loading on nanoparticles zeta potential. (Top Right) The effect of initial PTX 
loading on actual PTX loading (with and without poly(vinyl alcohol), PVA). (Bottom) 
Contour plots showing the effect of TFF flow rate and transmembrane pressure (TMP) 
on NP diameter at different initial paclitaxel (PTX) loadings. Regions where 
nanoparticles exhibited diameters of 150 nm or less on contour maps are indicated by 
arrows. 
 
5.6.2 Comparison of purification processes 
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5.6.2.1 Characteristics of PTX-NP, RSV-NP, and TAC-NP  
Following DOE analysis, NP were formulated using optimized parameters using 
both TFF and centrifugation purification processes to compare their effects and the 
impact of different drugs on NP characteristics when other small molecules are used. 
As shown in Figure 5.4, the size of PTX-NP and TAC-NP decreased after TFF and 
increased after centrifugation, whereas the diameter of RSV-NP decreased after both 
TFF and centrifugation. In comparison to centrifugation, TFF resulted in significantly 
smaller-sized particles for PTX-NP and TAC-NP, but not RSV-NP. NP PDI values 
exhibited no significant change post-purification except for a significant increase for 
TAC-NP following centrifugation. The zeta potential values of the NP decreased 
significantly after both purification methods.  
PVA content of the NP formulations was significantly higher in TFF-purified NP 
in comparison to centrifugation-purified NP. Furthermore, PVA content increased for 
TFF-purified NP (due to the addition of 0.05% PVA) and decreased for centrifugation-
purified NP (due to the washing steps). SEM images of PTX-NP (Figure 5.5) show 
the morphological similarities of particles purified via TFF compared to particles 
purified via centrifugation and the extent of PVA coverage in the samples prior to 
washing. The morphology of NP following TFF and centrifugation purification were 
spherical with smooth surfaces. The presence of PVA is greater in NP samples 
purified using TFF in comparison to particles purified via centrifugation, which 
correlates to the PVA quantification data.  
Following TFF, DL values were higher for PTX-NP and RSV-NP, but not for 
TAC-NP, and DL values (with or without PVA) were higher for PTX-NP and TAC-
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NP, but not for RSV-NP following centrifugation. In addition, DL values were 
significantly higher for PTX-NP and RSV-NP purified via TFF in comparison to 
centrifugation, whereas there was no difference for TAC-NP. DL was the highest for 
PTX-NP and the lowest for RSV-NP following centrifugation. DL increased upon the 
subtraction of PVA from the samples. 
 
 
Figure 5.3. Characteristics of paclitaxel (PTX), tacrolimus (TAC), and resveratrol 
(RSV)-loaded nanoparticles (NP) before purification and after tangential flow 
filtration (TFF) and centrifugation purification processes. *p < 0.05, **p < 0.01, ***p 
< 0.001, and ****p < 0.0001. Mean ± standard deviation, n = 3. 
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Figure 5.4. Representative scanning electron micrographs of paclitaxel nanoparticle 
formulations purified via (Left) centrifugation and (Right) tangential flow filtration 
(TFF). Particles are shown with (Top) poly(vinyl alcohol) (PVA) present and 
(Bottom) in the absence of PVA. Scale bar = 500 nm. 
 
5.6.2.2 Effects of purification steps 
The drug and PVA content of samples taken at different stages of the purification 
processes (Figure 5.1) were evaluated to understand the effect of the processing steps 
on these parameters. As shown in Figure 5.6, little drug loss occurred during the 
concentration step of centrifugation, whereas significant drug loss occurred during the 
washing step. In correlation, a significant amount of PVA was removed from the NP 
samples during the centrifugation and less was removed during the washing step. 
During TFF, there was negligible drug loss during the diafiltration and concentration 
steps, whereas a significant amount of drug was present for the membrane cleaning 
step. The PVA content of the samples taken during TFF processing was high for all 
TFF purification steps.    
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Figure 5.5. Drug loading and poly(vinyl alcohol) (PVA) content of paclitaxel, 
tacrolimus, and resveratrol-loaded nanoparticle (PTX-NP, TAC-NP, and RSV-NP, 
respectively) suspensions taken during the centrifugation and tangential flow filtration 
purification processes. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. 
Mean ± standard deviation, n = 3. 
 
5.7 Discussion 
The main goal of this study was to determine the effects of key TFF parameters on 
NP characteristics. BBD factor levels for TFF purification were chosen based on the 
manufacturer’s recommendations for flow rate and TMP in accordance with the 
material type and pore size of the membrane used. In addition, centrifugation was used 
as a comparative purification method. The model molecules used in this study have 
slightly different chemical properties and structures (taxane, stilbene, and macrolide; 
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see Supplement Table S.1); however, they are all lipophilic, which makes them ideal 
candidates to be encapsulated into polymeric NP. PTX was chosen as the initial model 
drug due to its extensive use as an FDA-approved chemotherapeutic (249–252). RSV 
is a well-studied natural product that has demonstrated numerous pharmacological 
benefits such as anti-inflammatory and anti-cancer properties (253). TAC is one of the 
most widely used immunosuppressive therapeutics for post-operative organ 
transplantation (254–256).  
Several BBD factors (TFF parameters) had significant influences on the responses 
(NP characteristics). Varying TFF flow rate had an influence on the PDI of NP, where 
increasing the flow rate resulted in decreased PDI values. Smaller constituents (e.g. 
unencapsulated drug or smaller NP) can be more readily filtered out with a higher 
flow rate, resulting in more uniform particle sizes, and thereby decreasing PDI. This 
indicates that a high flow rate is desirable to achieve NP with a narrow size 
distribution. Although zeta potential was significantly influenced by the initial PTX 
loading (ZP increased as DL increased), the NP can be considered functionally neutral 
(79, 80). The initial PTX loading had a significant influence on the final PTX loading 
of the NP, where there was a positive correlation.  
The combination of flow rate and TMP significantly influenced the size of the NP 
formulations. By increasing the flow rate, the membrane exposure time decreases, 
which reduces the potential for membrane fouling. Thus, the resulting concentration 
gradient at the membrane surface allows smaller permeable species (free polymer, free 
drug, smaller particles, etc.) to pass through more readily through the membrane via 
passive diffusion. In turn, an increase in TMP drives more fluid through the 
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membrane, thereby increasing filtration capacity, but also increasing the potential of 
membrane fouling. In addition, increasing the TMP close to or beyond manufacturer 
recommendations risks the destruction of the membrane itself. Therefore, utilizing a 
high flow rate and low TMP were determined as the best-case scenario for achieving 
diameters within the range of 145 to 150 nm. Therefore, based on these results, a 
lower TMP, higher flow rate, and higher drug loading were selected for further 
studies. 
Following TFF parameter optimization, NP loaded with PTX, RSV, and TAC 
were formulated using the optimized TFF parameters (TMP = 2 psi, flow rate = 150 
mL/min, and initial drug loading = 10 wt%) and via centrifugation as a comparison of 
the effect of purification process on NP parameters when different small molecules are 
used. The increase in diameter and PDI for PTX-NP and TAC-NP following 
centrifugation was likely due to the agglomeration that occurred during centrifugation 
process. This phenomenon can potentially be attributed to the challenge in re-
dispersing NP pellets, the fact that smaller NP may not have been removed, and the 
lower zeta potential values, which may indicated less PVA coating as Ac-Dex is 
negatively charged. In comparison, the 500 kDa membrane used during TFF was able 
to retain NP  50 nm. The differences in diameters observed between TFF-purified NP 
and centrifugation-purified NP lies in the underlying mechanistic differences between 
the techniques. Centrifugation utilizes g forces to isolate the NP and is a type of dead-
end filtration (24). These forces, in addition to redispersion variability, can inherently 
result in larger NP diameters. In contrast, TFF utilizes a dynamic filtration process, 
where NP suspensions are constantly flowing tangentially to the membrane, which 
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prevents potential agglomeration while allowing for size exclusion purification (241, 
242).  
The decrease in zeta potential values post-purification can be attributed to the 
exposure of Ac-Dex on the NP surfaces during processing (Ac-Dex is slightly 
negatively charged) and overall the NP can be considered functionally neutral (79, 
80). During purification via centrifugation, NP suspensions were exposed to PVA-free 
media and the PVA was washed off the NP. In comparison, NP in the TFF membrane 
were diafiltrated with PVA-laden media, and as a result, the NP are exposed to more 
PVA, resulting in higher PVA content. In addition, variations in PVA content of post-
TFF samples were observed. Since the amount of PVA in suspension varies from 
batch-to-batch, the PVA content of final formulations often varies (23). NP 
purification via centrifugation resulted in lower PVA content compared with TFF. Due 
to its water solubility, PVA diffused into the fresh water during washing and was 
thereby removed from the surface of the NP during centrifugation. On the other hand, 
there was a higher volume of PVA-saturated media that remained unchanged in the 
diafiltration steps during TFF, resulting in higher PVA content for these samples.   
It has been shown that centrifugation often results in higher drug loading in 
comparison to TFF (23). However, in this study, TFF purification resulted in higher 
drug loading in comparison to centrifugation for PTX-NP and RSV-NP, and resulted 
in lower drug loading for TAC-NP. Overall, there were no trends related to changes in 
NP diameter, PDI, zeta potential, PVA content, or drug loading despite the 
fundamental differences in the physicochemical characteristics (chemical structure, 
molecular weight, Log P, or water solubility) of the model drugs investigated.  
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The large amounts of drug removed from the TFF membrane during membrane 
washing (Step 3) indicated significant interactions between the free drug or NP and the 
mPES membrane. The physicochemical characteristics of the model drugs play a role 
in drug-membrane interactions. For example, the drugs may result in high membrane 
adsorption due to their high Log P values. Molecular interactions such as hydrogen 
bonding (PTX and TAC), non-polar interactions (TAC), and pi-pi stacking (due to the 
presence of aromatic rings in RSV, PTX, and the mPES membrane) are other possible 
interactions that likely could have caused drug-membrane interactions, thereby 
influencing the outcome of the DL values of the formulations.  
 
5.8 Conclusions 
BBD was used to identify the influence of key TFF parameters, in addition to 
initial drug loading, on NP characteristics. It was found that NP characteristics were 
dependent on a multitude of factors, including TFF flow rate and TMP, the initial drug 
loading, and potential membrane-drug interactions. Upon comparison of the two 
purification methods, TFF results in difficulties in controlling PVA content and 
requires consideration for drug-membrane interactions and formulation dependent 
optimization. In contrast, centrifugation is able to reduce PVA content, but produces 
shear forces that can affect NP characteristics. TFF circumvents the issues associated 
with centrifugation. In addition, TFF is an automated process capable of both 
purification and filtration of NP, resulting in outcomes similar to that of, or better than, 
centrifugation.  
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6.1 Abstract 
Pulmonary arterial hypertension (PAH) is a progressive disease associated with 
structural remodeling of pulmonary vasculature. The excessive proliferation of the 
endothelial cells results in thicker vascular walls and eventually in increased 
pulmonary resistance. Currently, treatment for PAH is limited to improving quality of 
life, rather than treating the disease itself. Therefore, alternative approaches are being 
taken to treat and/or slow the progress of the disease. One approach is through 
activation of TMEM16A, a calcium-activated chloride channel. Studies have shown 
that TMEM16A represents a promising therapeutic target for PAH. Recently, a study 
demonstrated TMEM16A’s ability to induce apoptosis of pulmonary endothelial cells 
via p38-MAPK-induced apoptosis using Eact, a known activator of TMEM16A. 
Complimenting this previous study, the purpose of this study was to develop a 
nanocomposite microparticle (nCmP) delivery system for pulmonary administration of 
Eact. Results thus far demonstrate successful formation of nCmP, as well as their 
favorable deposition in a Next Generation Impactor. Overall, Eact is a polymorphic 
small molecule that needs to be further researched to properly develop a stable and 
usable formulation for the treatment of PAH. 
 
6.2 Keywords  
Acetalated dextran (Ac-Dex); Eact; pulmonary arterial hypertension; 
pulmonary drug delivery; nanocomposite microparticles  
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6.3 Abbreviations 
2-methoxypropene (2-MOP), acetalated dextran (Ac-Dex), bone morphogenetic 
protein receptor-2 (BMPR-2), cyclic-to-acyclic ratio (CAC), dichloromethane (DCM), 
dimethyl sulfoxide (DMSO), deionized (DI) water, differential scanning calorimetry 
(DSC), dynamic light scattering (DLS), encapsulation efficiency (EE), Karl Fischer 
Titration (KFT), nanocomposite microparticles (nCmP), nanoparticles (NP), Next 
Generation Impactor (NGI), phosphate buffered saline (PBS), poly(vinyl alcohol) 
(PVA), poly(lactic-co-glycolic acid) (PLGA), pyridium p-toluenesulfonate (PPTS), 
pulmonary arterial hypertension (PAH), polarized light microscopy (PLM), scanning 
electron microscopy (SEM), triethylamine (TEA), ultra performance liquid 
chromatography (UPLC), X-ray diffraction (XRD). 
 
6.4 Introduction 
Pulmonary arterial hypertension (PAH) is a progressive, life-threatening 
cardiovascular disease that is defined by an increase in mean pulmonary arterial 
pressure of the right side of the heart (257–259). This increase in pressure can be 
traced back to remodeling of the arterial walls, which can result from idiopathic causes 
(in most cases), or both genetic anomalies and environmental insults (53, 257). 
Ultimately, the remodeling and subsequent thickening of the arterial walls manifests 
from excessive proliferation and dysfunction of endothelial cells and inflammation 
(260). Currently, treatments for PAH are based on improving overall cardiopulmonary 
function and patient quality of life. However, these treatment options are generally 
unable to inhibit the progress of the disease (53).  
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Due to the challenges that lie with current treatment options, newer approaches 
are being taken to attempt to treat PAH, particularly through focus on cellular-based 
mechanisms (53). One approach in treating PAH is through improving the function of 
bone morphogenetic protein receptor-2 (BMPR-2) signaling pathway (259). Mutations 
to BMPR-2 account for approximately 60-80% of familial cases of PAH (255, 261, 
262). To capitalize on this approach, tacrolimus (TAC) has been explored as a possible 
therapeutic approach. Aside from its traditional use as an immunosuppressive agent 
(254), TAC has been shown to increase BMPR-2 signaling. Clinical evidence has 
shown improvements in patients suffering from PAH following treatment with low-
dose TAC, prompting research to further understand the underlying mechanism and 
potential use of it as a therapeutic option for the disease (263).  
 Another approach in the treatment of PAH is the activation of anoctamin-1 
(TMEM16A), which, like other calcium-activated chloride channels (CaCCs), is vital 
for physiological functions, and is expressed in epithelial and non-epithelial cells 
(264–266). In moments of dysfunction, TMEM16A can be associated with diseases 
including cancer, cystic fibrosis, and hypertension (265, 267–272). Specifically, an 
increase in expression of TMEM16A can lead to increased proliferation of cancer cells 
and a decrease in proliferation of smooth muscle tissue (258). Recently, TMEM16A 
activation by Eact was shown to promote apoptosis of pulmonary endothelial cells by 
the p38-MAPK signaling pathway (258). This apoptotic promotion can be a potential 
treatment method, given that the hyperproliferative phenotype of endothelial cells is a 
hallmark sign of PAH (258). Eact, the small molecule used in this study, was 
originally discovered using cell-based high-throughput screening (273). Prior to 2017, 
 126 
 
Eact research had been published in a limited amount of studies, primarily as a control 
or inducing agent (269, 274, 275).  
 Pulmonary delivery has received an increasing amount of attention for the 
treatment of diseases involving the lungs, primarily due to the potential for localized 
delivery to tissue and molecular sites of interest (145, 148, 276). In addition to 
localized delivery, pulmonary administration offers reduced systemic side effects, a 
rapid onset of action, and avoidance of first-pass metabolism (135, 277). Dry powder 
aerosols are a highly attractive method of pulmonary administration owing to the 
aforementioned advantages plus increased product stability (via absence of water) 
compared to other dosage forms such as nebulizers (145). Typically, dry powder 
aerosol particles in the range of < 500 nm are exhaled due to low mass, while particles 
that are 1 – 5 μm are likely to deposit in lower regions of the pulmonary system; 
however, particles within this range are susceptible to macrophage uptake (53). To 
overcome these obstacles, nanocomposite microparticles can be utilized. A nCmP 
involves nanoparticles (NP) entrapped in a microparticle matrix. nCmP maintain the 1 
- 5 μm size window, allowing for deep lung deposition via sedimentation (45), and 
following their deposition, nCmP dissociate to NP, allowing for avoidance of 
macrophage uptake.   
 This study involves the development and evaluation of a nCmP formulation 
encapsulating Eact, using acetalated dextran (Ac-Dex) as the polymeric carrier. In 
comparison to poly(lactic-co-glycolic acid) (PLGA), Ac-Dex can be produced using a 
single-step, facile reaction (53). This reaction can be controlled to alter the acetal 
coverage of the dextran backbone, allowing for alteration in the release kinetics 
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associated with its encapsulated cargo. Additionally, degradation of Ac-Dex produces 
neutral byproducts (acetone, methanol, dextran) and has been shown to be safe in vivo 
(19).  
 
6.5 Materials and Methods 
6.5.1 Materials  
Unless stated otherwise, all materials were purchased from Sigma Aldrich (St. 
Louis, MO). Eact was purchased from Tocris Bioscience (Bristol, UK).  
 
6.5.2 Synthesis and Characterization of Acetalated Dextran  
Acetalated dextran (Ac-Dex) was synthesized using previously described 
methods with minor modifications (40). 1 g of lyophilized dextran (MW 9,000 – 
11,000) was dissolved in 10 mL of anhydrous DMSO with 30 mg of p-
toluenesulfonate (PPTS) under nitrogen gas. The reaction was carried out for 3 hours 
by adding 6.5 mL 2-methoxypropene (2-MOP), and the reaction was quenched after 5 
minutes using 1 mL of triethylamine (TEA). The polymer was precipitated in basic 
water, filtered, lyophilized, and stored at -20°C. The cyclic-to-acyclic (CAC) ratio of 
Ac-Dex and acetal coverage was verified using 1H NMR (Bruker 300 MHz, NMR, 
MA) as described previously (54).  
 
6.5.3 Synthesis of Eact-Encapsulated Nanoparticles 
 NP encapsulating 10% (w/w) Eact were synthesized using single 
emulsion/solvent evaporation method. 36 mg of Ac-Dex and 4 mg of Eact were 
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dissolved in 1 mL of dichloromethane (DCM) containing 0.01% (w/w) QD. This 
organic solution was added to 6 mL of 3% poly(vinyl alcohol) (PVA), and the mixture 
was emulsified using a probe sonicator attached to an ultrasonic processer at 120 W 
and 20 kHz for 30 seconds, with 1 second on/off pulses and an amplitude of 70%.  
 
6.5.4 nCmP Synthesis Via Spray Drying 
 nCmP were made using previously established methods, using a Buchi B-290 
spray dryer (Buchi Labortechnik, AG, Switzerland) (44, 45). Briefly, NP batches were 
combined, diluted to 10 mg/mL, and sonicated for 10 minutes prior to spray drying.  
The spray drying conditions were inlet temperature of 70°C, 0.7 mm nozzle diameter, 
atomization gas flow rate of 414L/h (nitrogen), aspiration of 28m3/h, pump rate of 0.9 
mL/min, and nozzle cleaner rate of 3 (45). Following spray drying, the resulting nCmP 
were allowed to dry in the cyclone under nitrogen gas for an additional 15 minutes. 
The nCmP were collected in an amber glass vial and stored at -20 °C under 
desiccation until use.  
 
6.5.5 Nanoparticle Size and Surface Charge Characterization  
 The hydrodynamic diameter and surface charge of the NP and re-dispersed NP 
were evaluated via dynamic light scattering (DLS) and zeta potential analysis, 
respectively, using a Malvern Nano Zetasizer (Malvern Instruments, Worcestershire, 
UK). The parent NP and re-dispersed NP were diluted to 0.25 mg/mL in DI water, and 
were analyzed at 25°C and an angle of 90°.  
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6.5.6 Particle Morphology and Shape Analysis via Scanning Electron Microscopy 
(SEM) 
 The shape and morphology of nCmP, NP, and raw Eact were evaluated by 
SEM using a Zeiss SIGMA VP Field Emission-Scanning Electron Microscope (FE-
SEM) (Germany). NP samples were concentrated to 15 mg/mL and 1 μL of the 
resulting suspension was added to aluminum SEM stubs prior to drying (Ted Pella, 
Inc., Redding, CA). nCmP and raw Eact samples were added directly to double-sided 
adhesive carbon tabs. The samples were sputter coated with a thin film of 
gold/palladium alloy under argon gas. Images were taken at 5 kV at various 
magnifications.  
 
6.5.7 Crystallinity and Phase Transition Analysis  
Thermal phase transitions of the nCmP and raw materials were analyzed via 
differential scanning calorimetry (DSC) using a TA Q10 DSC system (TA 
Instruments, New Castle, DE) connected to an RSC-90 cooling accessory. 3-5 mg of 
sample were hermetically sealed in aluminum pans and were placed into the DSC 
furnace. Samples were heated from 0-230°C at a rate of 10°/min (45). The crystallinity 
of the nCmP and raw materials were examined by X-ray diffraction (XRD) using a 
Rigaku Multiflex X-ray diffractometer (The Woodlands, TX) as described previously 
with a scan range of 5-60° in 2Θ with a width of 0.1 and scan rate of 1°/min. (45). 
Images of the nCmP and raw materials were observed for birefringence via polarized 
light microscopy (PLM) using an AmScope polarized microscope (Irvine, CA) (225, 
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278). Samples were mounted onto microscope slides, smeared with mineral oil for 
dispersion, and imaged at 10x at room temperature.  
 
6.5.8 Karl Fischer Coulometric Titration  
 The water content of nCmP was quantified by Karl Fischer (KF) titration using 
a 737 KF coulometer (Metrohm, Riverview, FL). 5 mg of powder was dissolved in 
anhydrous methanol. The solution was injected into the reaction cell filled with 
Hydranal® KF reagent, and the amount of water was analyzed. Pure solvent was 
injected as a background sample.   
 
6.5.9 In Vitro Aerosol Performance 
 In vitro aerosol performance of the nCmP was evaluated using a Next 
Generation Impactor (NGI, MSP Corporation, Shoreview, MN) equipped with a 
stainless steel induction port attachment and gravimetric insert cups. The system was 
coupled with a TPK 2000 critical flow controller and HCP5 vacuum pump (Copley 
Scientific, UK). The air flow rate (Q) was measured and adjusted to 60 L/min prior to 
each experiment to simulate breath flow by healthy human patients. Fiber glass filters 
(55 mm, Type A/E, Pall Life Sciences, PA) were placed in the insert cups for stages 1 
to 7 for the minimization of MP bounce or re-entrapment (279). Filters were weighed 
before and after experiments to determine nCmP amount deposited in each stage. 8-12 
mg of powder was loaded into hydroxypropyl methylcellulose capsules (HPMC, size 
3, Quali-V®, Quali-caps Inc., Whitsett, NC, USA). The capsules were then loaded into 
a dry powder inhaler (HandiHaler, Boehringer Ingelheim Pharmaceuticals, CT) and 
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the system was attached to a customized rubber mouthpiece connected to the NGI. 
Experiments were performed in triplicate with a 10 s delay and 10 s running time. For 
Q = 60 L/min, effective cutoff diameters of each stage are as follows: stage 1 (8.06 
µm), stage 2 (4.46 µm), stage 3 (2.82 µm), stage 4 (1.66 µm), stage 5 (0.94 µm) stage 
6 (0.55 µm) and stage 7 (0.34 µm). Fine particle fraction (FPF), respirable fraction 
(RF), and emitted dose (ED) were calculated using the following equations: 
 
Fine	Particle	Fraction	(FPF)	=	
Mass	of	MP	on	stages	2	through	7
Total	MP	mass	on	all	stages
	x	100%
 
 
 
 
Respirable	Fraction	(RF)	=	
Mass	of	MP	on	stages	2	through	7
Initial	MP	mass	loaded	into	capsules
	x	100%
 
 
 
	
Emitted	Dose	(ED)	=	
Initial	MP	mass	in	capsules	-	Final	MP	mass	in	capsules
Initial	MP	mass	in	capsules	
	x	100%    
 
The experimental mass median aerodynamic diameter (MMADE) and 
geometric standard deviation (GSD) for nCmP were determined using Mathematic® 
program written by Dr. Warren Finlay (224).  
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6.5.10 Encapsulation Efficiency and Drug Loading Analysis  
 Encapsulation efficiency and drug loading of Eact encapsulated in NP were 
determined using Ultra Performance Liquid Chromatography (UPLC, LaChrom, 
Hitachi, Japan). Detection of Eact was performed using: C18 5 μm x 150 mm x 4.6 mm 
column (Ascentis, Sigma-Aldrich, St. Louis, MO), 1 mL/min pump rate, mobile phase 
of 70:30 acetonitrile: 0.1% (30% phosphoric acid) aqueous solution, absorbance at 280 
nm and temperature of 50°C. Drug loaded NP were  fully dissolved in mobile phase 
prior to analysis. The EE and DL of Eact loaded NP were determined by the following 
equations:  
 
 
 
 
6.5.11 Statistical Analysis 
 All measurements were performed in at least triplicate. Statistical significance 
was determined using Student’s t-test. A p value of < 0.05 was considered as 
statistically significant. Values were presented as mean ± standard deviation unless 
stated otherwise.  
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6.6 Results and Discussion 
6.6.1 Morphology Analysis of NP and nCmP  
In this study, 3-hour Ac-Dex was used for nanoparticle (NP) synthesis due to 
its ability to control the release of therapeutic cargo at physiological conditions for a 
longer period of time than 5-min Ac-Dex (36, 45). This phenomenon is due to the 
higher ratio of cyclic acetal groups to acyclic groups in 3-hour Ac-Dex compared to 5-
min Ac-Dex, allowing for slower degradation over time (35). In previous studies, it 
was shown that both 5-min and 3-hour Ac-Dex allowed for sustained release of 
various lipophilic compounds, however, 3-hour Ac-Dex resulted in longer release of 
these compounds (35, 43, 45).   
As shown in Table 6.1, Eact-loaded NP were 191 nm in diameter, with 
favorable polydispersity (0.11) and surface charge (functionally neutral; -4.18 mV). 
The loading of Eact in the Eact NP formulation was 27.6 μg Eact/mg NP with an 
overall Eact encapsulation efficiency of 25.9%. Following spray drying, nCmP were 
re-dispersed in DI water to allow for dissociation into parent Eact NP. Like parent NP, 
re-dispersed Eact-loaded NP were less than 200 nm in diameter, with similar PDI 
(0.11) and surface charge (-4.20 mV). Statistical analysis showed that the two groups 
were not significantly different from one another (p > 0.05). Parent Eact NP and Eact 
NP re-dispersed from nCmP exhibited smooth and spherical morphology, whereas 
nCmP were agglomerations of NP with corrugated structure (Figure 6.1).  
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Table 6.1. Physical characteristics of Eact-loaded nanoparticles (NP) and 
nanocomposite microparticles (nCmP) including the diameter, polydispersity index 
(PDI), surface charge via zeta potential, drug loading, encapsulation efficiency (EE), 
water content, and PVA surface content. 
 
Diameter 
(nm) PDI 
Charge 
(mV) 
Drug Loading 
(μg Eact/mg 
NP) 
EE 
% 
Blank NP 157.6 ± 2.3 0.10 ± 0.02 N/A N/A N/A 
Eact NP 190.9 ± 8.2 0.11 ± 0.05 -4.18 ± 2.45 27.6 ± 8.8 
25.9 
± 
8.6 
Re-Dispersed 
Eact NP 196.8 ± 2.0 0.11 ± 0.02 -4.20 ± 0.92 N/A N/A 
 
Water Content (%) 
PVA Surface Content 
(mg PVA/mg nCmP) 
Eact nCmP 4.61 ± 1.90 0.095 ± 0.002 
 
 
 
Figure 6.1. SEM micrographs of raw Eact, parent Eact nanoparticles (NP), Eact 
nanocomposite microparticles (nCmP), and NP re-dispersed from nCmP. 
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The formation of the corrugated nCmP structures are a result of the spray-
drying process (45). Following suspension of NP in water, the suspension is exposed 
to the drying gas, resulting in NP dispersed in droplets. As water evaporates, NP are 
transported to the outside of the droplet due to droplet saturation (280). Once drying 
occurs the droplet walls collapse, resulting in corrugation (145). The hollow structure 
of the particles results in lower particle density, altering the overall aerodynamic 
diameter, and increasing flowability during patient inspiration (146). Additionally, due 
to their ability to dissociate into NP following sedimentation, nCmP are able to 
delivery NP to the latter depths of the lungs (44).  
 
6.6.2 Solid-State Analysis of nCmP  
 X-ray diffractograms of raw Eact, Eact nCmP, and raw 3-hour Ac-Dex are 
shown in Figure 6.2A. Raw Eact exhibited strong signals corresponding to 
crystallinity, whereas Ac-Dex showed no distinct peaks, indicating an amorphous 
physical characteristic. Eact nCmP exhibited fewer peaks, although several strong 
visible peaks were present. It is possible that the lack of peaks is due to a detection 
limitation of the equipment, in addition to the lower drug loading. DSC thermograms 
of raw Eact showed a melting peak at 105°C (Figure 6.2B), whereas no observable 
transitions were observed for raw 3-hour Ac-Dex. Following spray drying and 
formation of the nCmP, two endothermic peaks were seen at 155°C and 200°C for 
Eact nCmP, corresponding to possible polymorphs of Eact. Prior to the melting of 
Eact nCmP at 200°C, brief re-crystallization may have occurred at 155ºC, signifying 
an increase in molecular mobility and subsequent re-crystallization to form another 
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crystalline structure (281, 282). Polarized light microscopy (PLM) images (Figure 
6.2C) corresponded to both XRD and DSC profiles, signifying amorphous 
characteristics for raw 3-hour Ac-Dex, crystallinity of raw Eact, and crystallinity of 
Eact nCmP, as evident by the birefringency in the polarized light samples. Combining 
these data with the low water content of the nCmP (< 5%) (Table 6.1) provides 
evidence that the formation of nCmP altered the physical characteristics of Eact to a 
less crystalline state while maintaining minimal water content (145). Results indicate 
that Eact is a crystalline small molecule, however, more studies need to be carried out 
to assess if polymorphs exist and if molecular rearrangements occurred (281, 283, 
284).  
 
 
Figure 6.2. (A) Representative x-ray diffractograms, (B) representative differential 
scanning calorimetry thermograms and (C) polarized light microscopy images of raw 
materials (3-hour Ac-Dex and Eact) and Eact-loaded nCmP. Scale bar = 0.1 mm. 
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6.6.3 Aerosol Performance Characterization of nCmP 
In vitro aerosol performance of nCmP was evaluated using a Next Generation 
Impactor (NGI) coupled to a dry powder inhaler. nCmP deposited on all stages of the 
NGI (Figure 6.3), indicating the potential for the particles to deposit in multiple areas 
of the lungs. The high fine particle fraction (>96%, Table 6.2) indicates that a 
significant portion of the particles are capable of aerosolization (53, 54). In addition,  
RF and ED were similar or higher than previously published studies, and indicate that 
inhalation of nCmP aerosols would likely result in effective particle delivery to the 
lungs. MMADE values were within the 1-5 μm range necessary for deep lung 
deposition (45), while geometric standard deviation (GSD) was higher compared to 
previous studies (45, 49, 53, 153, 285). The high GSD is likely due to unequal 
agglomeration of the NP when forming the nCmP (44). PAH is a cardiopulmonary 
related disease, and would benefit from deep lung deposition due to the high 
vascularization of alveolar tissue and location of the arterial walls of the heart (53, 
142, 257). While MP have shown the capability for deep lung deposition, a previously 
published study evaluated the aerosol performance between nCmP and MP. Results 
indicated that nCmP were able to better deposit in latter stages of the NGI compared to 
MP. Due to the location of PAH, utilization of nCmP formulations may be more 
beneficial than MP (45).  
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Figure 6.3. Aerosol dispersion analysis of Eact-loaded nanocomposite nanoparticles 
(Eact nCmP) in stages 1-7 of a Next Generation Impactor, expressed as percent 
particle deposition per stage (mean ± standard deviation, n = 3). For Q = 60 L/min, 
cutoffs for each stage of the NGI are: 8.06 µm (stage 1), 4.46 µm (stage 2), 2.82 µm 
(stage 3), 1.66 µm (stage 4), 0.94 µm (stage 5), 0.55 µm (stage 6) and 0.34 µm (stage 
7). 
 
Table 6.2. Aerosolization performance properties of spray-dried Eact-loaded 
nanocomposite microparticles (Eact nCmP), including fine particle dose (FPD), fine 
particle fraction (FPF), respirable fraction (RF), emitted dose (ED), experimental mass 
median aerodynamic diameter (MMADEXP), and geometric standard deviation (GSD) 
via Next Generation Impactor analysis (mean ± standard deviation, n = 3). 
Particles 
FPD 
(mg) 
ED 
(mg) 
FPF 
(%) 
RF  
(%) 
ED 
(%) 
MMADEXP 
(μm) 
GSD 
(μm) 
Eact 
nCmP 
17.2  ± 
0.4 
25.3  ± 
0.5 
96.8 ± 
2.3 
70.5  ± 
0.3 
98  ± 
1.4 2.68 ± 0.24 
2.88 ± 
0.34 
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6.7 Conclusions 
An aerosol nCmP system was developed for the delivery of the novel 
therapeutic Eact that can be used to treat pulmonary arterial hypertension. Results thus 
far show that Eact was successfully encapsulated in 3-hour Ac-Dex NP and that the 
resulting NP were successfully formulated into nCmP. The size of NP before nCmP 
synthesis and after dissociation from the nCmP were below 200 nm and were similar 
with respect to surface charge and PDI, providing evidence that NP characteristics 
were not altered following encapsulation in and release from nCmP. XRD data 
indicated changes in Eact crystallinity following nCmP formation. In addition, DSC 
thermograms showed the presence of two crystalline states in Eact nCmP, indicating 
the polymorphic nature of Eact. The water content of nCmP were below 5%. Finally, 
nCmP showed favorable aerosol performance, capable of depositing in all stages of 
the NGI. Overall, Eact-encapsulated nCmP may be a favorable delivery system for 
Eact for the treatment of PAH in a patient convenient and effective manner. However, 
the polymorphic nature of Eact must be evaluated further and the crystallinity of Eact 
may need to be controlled through the use of additional polymers.  
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CHAPTER 7 
 
CONCLUSIONS AND FUTURE WORK 
   
 
7.1 Conclusions 
      This primary focus of this dissertation was on the exploration of the polymer 
acetalated dextran (Ac-Dex) as a versatile drug carrier that has the potential to 
overcome contemporary obstacles in drug delivery. One of the main obstacles faced in 
drug delivery applications is drug toxicity and a cause of this is the typical lack of 
active targeting for drug delivery systems to reach desired tissues. To actively target 
macrophages in an effort to combat this obstacle, Ac-Dex nanoparticles (NP) were 
coated in phosphatidylserine (PS) to mimic apoptotic cells. Results indicated minimal 
toxicity of the NP delivery systems, as well as significant PS NP uptake by 
macrophages, providing evidence that active targeting is achievable using Ac-Dex-
based nanoparticle formulations.  
      Sustained release of therapeutics is an ongoing research interest, for both lipophilic 
and hydrophilic entities. However, the release of hydrophilic entities is inherently 
more difficult to control, given their solubility in biological medium and the inability 
to control the release of these entities can generate another avenue for drug toxicity. 
Taking advantage of Ac-Dex’s hydrophobicity and tunability, multiple aerosol powder 
formulations were synthesized via spray drying to modify the release behavior of a 
highly water-soluble dye. Results show that the release kinetics were both pH and 
 141 
 
polymer tunability dependent, where sustained release was reached in physiological 
conditions and controlled release was achieved in acidic conditions. In addition, 3-
hour and 5-minute Ac-Dex experienced differences in their kinetic analysis, where the 
former resulted in slower release of a water-soluble compound. 
      During the production of nanoscale delivery systems, purification methods are 
employed to ensure that the desired product is collected and packaged prior to usage.  
However, conventional methods of purification may be inefficient, especially when 
scale-up approaches are needed. To overcome this challenge, tangential flow filtration 
was evaluated using a DoE approach to understand the influence of key parameters on 
NP characteristics using Ac-Dex as a model carrier. Following this, a set of parameters 
were chosen, and using these parameters, NP were synthesized, encapsulating one of 
three small molecules. Results show that tangential flow filtration is a suitable 
purification method but requires drug, system, and external factor considerations.  
      PAH is a life-threatening disease with no known treatment options. Current 
therapeutics for the disease rely on improving quality of life rather than slowing the 
progress of the disease. Eact, a TMEM16A activator, has been shown to induce 
apoptosis of hyperproliferating pulmonary endothelial cells, and can serve as a 
possible route of treatment. Utilizing the rationale described previously, nCmP were 
developed with the intention of pulmonary administration to increase localization and 
subsequent absorption of Eact into the cardiopulmonary regions of the body. 
Preliminary data shows that nCmP encapsulating Eact were successful in depositing in 
latter stages of an NGI, simulating deep lung deposition. It was also determined that 
 142 
 
Eact is a highly-crystalline, polymorphic small molecule that requires further 
exploration into both the polymorphs and possible formulation development.    
7.2 Future Work 
     Although this dissertation provides a comprehensive evaluation of Ac-Dex and its 
promise as a drug carrier, there are still opportunities to further research the 
biopolymer. These opportunities include 
1. The use of Ac-Dex in other delivery systems not mentioned here or in literature.  
2. Investigation of Ac-Dex-based systems designed here using disease models and 
active pharmaceuticals.  
3. Use of in vivo models to demonstrate the potential of the systems described and 
researched in this dissertation.  
4. Completion of studies that were based on preliminary data.  
5. Usage of other polymers to aid in Ac-Dex’s encapsulation.  
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APPENDIX A 
 
Supplementary Material for Chapter 3 
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Figure A1. Chemical Structures of DPPS (A), Ac-Dex (B), and Curcumin (C). 
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Figure A2. NMR Spectra of Ac-Dex with normalization integrations relating to 
associated peaks of methanol, acetone, and carbon ring of dextran. 
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Figure A3. Wet state DSC of the nanoparticle systems. 
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Figure A4. Diameter (left) and zeta potential (right) of Blank-PVA nanoparticle (A), 
Blank-DPPS nanoparticle (B), CUR-PVA nanoparticle (C), and CUR-DPPS 
nanoparticle (D) systems.  
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APPENDIX B 
 
Supplementary Material for Chapter 4 
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B.1 Materials 
The following chemicals were used: dextran from Leuconostoc mesenteroides 
(9,000-11,000 MW), pyridinium p-toluenesulfonate (PPTS, ≥ 99.9%), 2-
methoxypropene (2-MOP, ≥ 97%), triethylamine (TEA, ≥ 99%), anhydrous dimethyl 
sulfoxide (DMSO, ≥ 99.9%), deuterium chloride (DCl, 35 wt% in D2O, ≥ 99% atom 
D), sodium acetate (≥ 99%), acetic acid (1.0 N), chloroform (≥ 99%), anhydrous 
methanol (≥ 99.9%), and isopropanol (≥ 99%), sulforhodamine B sodium salt (SRB), 
Hydranal® KF reagent, and deuterium oxide (D2O, 99.8% atom D). All cell culture 
materials were purchased from American Type Culture Collection (ATCC, Manassas, 
VA, USA), Caisson Labs (Smithfield, UT, USA), or Fisher Scientific. 
 
B.1.1 Kinetics and Release Models 
The zero-order model describes the constant, controlled release of drug from a 
drug formulation, disregarding changes in equilibrium and erosion of the formulation 
(286). Ideal delivery of drugs would follow zero-order kinetics to keep blood levels 
constant. The zero-order model is described by: 
 
	
M
t
=K
0
t +M
0     
     
where Mt is the mass of drug released at time t, M0 is the initial mass of drug released 
at t = 0, and K0 is the zero-order release rate constant.  
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The first-order model describes drug release profiles as proportional to the 
amount of unreleased drug remaining at time, t, thereby indicating sustained release of 
the drug (286), as described by:  
 
	
logC
t
= logC
0
+
K
1
2.303
t
    
    
where Ct is the concentration of drug at time t, C0 is the initial drug concentration at t 
= 0, and K1 is the first-order release rate constant. 
 The Higuchi model describes drug release profiles based on square root time 
dependence (286) as seen in: 
 
     	
M
t
M
¥
= K
H
t1/2
     
     
where Mt/M∞ is fraction of drug released at time t and KH is the Higuchi dissolution 
constant. 
 The Korsmeyer-Peppas (K-P) model (a.k.a. Ritger-Peppas model) is a semi-
empirical model that exponentially relates the amount of drug released with time (286) 
as seen in: 
 
     	
M
t
M
¥
= K
KP
t n
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where Mt/M∞ is fraction of drug released at time t, KKP is the Korsmeyer-Peppas 
release rate constant that characterizes the structural and geometric properties of the 
particles, and n is the drug release exponent indicating the drug release mechanism. 
The K-P model allows for the understanding of the type of dissolution mechanism 
occurring during degradation, where an n value of 0.43 indicates Fickian diffusion, n 
of 0.85 indicates case II transport (erosion), and 0.43 < n < 0.85 indicates anomalous 
drug transport. 
 The Corrigan model is used to model burst release kinetics by combining 
contributions from first-order kinetics and polymer degradation, where release of drug 
molecules close to the surface of the system and polymer degradation are both 
contributions to release (234, 235). 
 
    	
Q =
M
t
M¥
= F
B ,in
1-exp -K
C
t( )( )
   
    
where Q is the fraction of drug released at time t, FB,in is the fraction of drug released 
during burst, and KC is the first-order Corrigan rate constant associated with the 
kinetics of the burst release (227). 
 The Peppas-Sahlin model (236, 237) accounts for both Fickian diffusion (first 
term in equation) and case II relaxation (second term in equation) release 
contributions: 
     	
M
t
M
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1
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2
t2m
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where Mt/M∞ is fraction of drug released at time t, k1 and k2 are the kinetic constants, 
and m is the diffusional exponent. The ratio of relaxation versus Fickian contributions 
can be calculated from: 
 
     	
R
F
=
k
2
k
1
tm
     
     
where R/F = 1 indicates a release mechanism contains both erosion and diffusion 
equally, R/F > 1 indicates that relaxation (erosion) dominates, and R/F < 1 indicates 
that diffusion dominates. 
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Table B1. Geometric diameter and zeta potential of microparticles systems (mean ± 
standard deviation, n = 3). 
System Geometric 
diameter (dg) (µm) 
Zeta Potential 
(mV) 
Fast-100C-MedP 1.13  ± 0.56 -16.1 ± 2.3 
Fast-150C-MedP 0.53  ± 0.19 -15.9 ± 1.8 
Fast-100C-HighP 1.11  ± 0.45 -13.5 ± 3.3 
Slow-100C-MedP 1.15  ± 0.51 -15.0 ± 1.5 
Slow-150C-MedP 1.01  ± 0.51 -15.9 ± 3.3 
Slow-100C-HighP 0.556  ± 0.24 -17.6 ± 1.8 
Man-100C-LowP 3.53  ± 2.3 --- 
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Table B2. Values for ratio of relaxation versus Fickian contribution (R/F) of Peppas-
Sahlin drug release kinetics model for microparticle drug release at pH 5. F100M = 
Fast-100C-MedP, F150M = Fast-150C-MedP, F100H = Fast-100C-HighP, S100M 
= Slow-100C-MedP, S150M = Slow-150C-MedP, S100H = Slow-100C-HighP. 
Time (hour) F100M F150M F100H S100M S150M S100H 
0 0 0 0 0 0 0 
1 0.2418 0.1931 0.1874 0.3134 0.6070 0.2364 
2 0.2575 0.1719 0.1967 0.3277 0.6370 0.2461 
4 0.2743 0.1813 0.2064 0.3426 0.6684 0.2562 
6 0.2847 0.1970 0.2123 0.3517 0.6874 0.2624 
8 0.2922 0.1911 0.2167 0.3582 0.7013 0.2667 
24 0.3230 0.2078 0.2340 0.3844 0.7569 0.2843 
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Figure B1. Total particle mass (mg) of aerosolization performance properties of 
particles, including fine particle fraction (FPF), respirable fraction (RF), and emitted 
dose (ED) (mean ± standard deviation, n = 3). 
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Supplementary Material for Chapter 5 
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C.1. Physical characteristics of drug molecules 
The physical characteristics of PTX, TAC, and RSV were acquired from 
www.drugbank.ca (accessed August 28th, 2018) (University of Alberta and The 
Metabolomics Innovation Centre, Edmonton, Alberta, Canada) or www.acdlabs.com 
(accessed August 30th, 2018) (Toronto, Ontario, Canada) and their chemical 
characteristics and molecular structures are shown in Table C1.   
 
Table C1. Chemical structures and characteristics of the encapsulated model 
therapeutics paclitaxel (PTX), tacrolimus (TAC), and resveratrol (RSV). 
Characteristics include molecular weight (MW), partition coefficient (Log P), and 
water solubility. Predictions for characteristics were calculated using ACDLabs.com 
and retrieved from drugbank.ca. 
Characteristics Paclitaxel (PTX) Tacrolimus (TAC) Resveratrol (RSV) 
 
 
 
Chemical 
Structure 
 
 
 
 
 
 
 
 
 
 
MW (g/mol) 853.9 804.0 228.2 
Log P 3.54 5.59 3.40 
Water 
Solubility 
(μg/mL) 
5.56 4.02 68.80 
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C.2 Ultra performance liquid chromatography (UPLC) analysis  
The quantification of PTX, TAC, and RSV was conducted using UPLC (LaChrom, 
Hitachi, Japan). A C18 column (5 µm, 150 mm  4.6 mm, Ascentis, St. Louis, MO) 
was used at a flow rate of 1 mL/min. For PTX and TAC content determination, the 
mobile phase consisted of 70% (v/v) acetonitrile (ACN) and 30% (v/v) aqueous 
phosphoric acid (0.1%, v/v) and the column temperature was set at 50°C. The UV 
wavelengths were 227 nm and 215 nm, respectively. For RSV content determination, 
the mobile phase was 50% ACN and 50% water containing 0.1% trifluoroacetic acid. 
The column temperature was set at room temperature and the UV wavelength was set 
at 306 nm.  
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